Matrix Metalloproteinases and Their Inhibitors in Normal and Aberrant Wound Repair : Expression patterns of collagenases-1 and -3, stromelysins-1 and -2, matrilysin, metalloelastase and TIMPs-1, -2, -3 and -4 in healing cutaneous wounds and in chrome ulcers of the skin and the intestine by Vaalamo, Maarit
Maarit Vaalamo
MATRIX METALLOPROTEINASES
AND THEIR INHIBITORS
IN NORMAL AND ABERRANT WOUND REPAIR
Expression patterns of collagenases-1 and -3, stromelysins-1 and -2,
matrilysin, metalloelastase and TIMPs-1, -2, -3 and -4  in healing
cutaneous wounds and in chronic ulcers of the skin and the intestine
University of Helsinki
Helsinki 2000
From the Department of Dermatology and Venereology,
 Helsinki University Central Hospital, Helsinki, Finland
MATRIX METALLOPROTEINASES AND THEIR INHIBITORS IN
NORMAL AND ABERRANT WOUND REPAIR
Expression patterns of collagenases-1 and -3, stromelysins-1 and -2, matrilysin,
metalloelastase and TIMPs-1, -2, -3 and -4 in healing cutaneous wounds
and in chronic ulcers of the skin and the intestine
by
Maarit Vaalamo
Academic Dissertation
To be presented, with the assent of the Medical Faculty of the University of Helsinki, for public
examination in the Lecture Room of the Department of Dermatology and Venereology, Helsinki
University Central Hospital, Helsinki, on  February 4th, at 12 o`clock noon.
Helsinki 2000
Supervised by
Docent Ulpu Saarialho-Kere
Department of Dermatology and Venereology
Helsinki University Central Hospital, Finland
Reviewed by
Professor Aarne Oikarinen
Department of Dermatology
University of Oulu, Finland
and
Docent Matti Laato
Department of Surgery
University of Turku, Finland
Opponent
Professor Jyrki Heino
Department of Biological and Environmental Sciences
University of Jyväskylä, Finland
ISBN 951-45-8992-0 PDF version)
      
Helsingin yliopiston verkkojulkaisut
Helsinki 2000
To Mikko, Emilia and Veikka
5CONTENTS
1.  List of original publications 7
2.  Abbreviations 8
3.  Abstract 9
4.  Introduction 10
5.  Review of the literature 11
5.1.  Structure of the skin and gut 11
5.1.1.  Epithelium 11
5.1.2.  Basement membrane 12
5.1.3.  Connective tissue 13
5.2.  Wound healing 16
5.2.1.  Cutaneous wound healing 16
5.2.2.  Intestinal wound healing 19
5.3.  Chronic cutaneous wounds 20
5.4.  Inflammatory bowel disease 21
5.5.  Matrix degrading enzymes 21
5.5.1. Matrix metalloproteinases 22
5.5.1.1. Collagenases 22
5.5.1.2. Gelatinases 24
5.5.1.3. Stromelysins 24
5.5.1.4. Membrane-type metalloproteinases 25
5.5.1.5. Other matrix metalloproteinases 26
5.5.2. Regulation of the matrix metalloproteinases 26
5.5.2.1. Regulation at the transcriptional level 26
5.5.2.2. Zymogen activation 27
5.5.2.3.  Inhibition of the activity of metallo-
proteinases 28
5.5.2.4.  Tissue inhibitors of metalloproteinases
(TIMPs)         28
5.6. Matrix metalloproteinases in cutaneous wound repair 29
5.7. Matrix metalloproteinases in intestinal disease 32
5.8. Matrix metalloproteinases in wound repair in other tissues 32
5.9. Matrix metalloproteinases as targets of wound therapies 33
6. Aims of the study 34
7. Materials and methods 35
7.1. Tissue samples 35
7.2. RNA probes 36
7.3. In situ hybridization 37
7.4. Immunohistochemistry 37
7.5. Cell cultures 38
7.6. Northern blot analysis 39
8. Results 40
8.1. Cutaneous wounds (II, III, V) 40
8.2. Intestinal ulcerations (I, IV) 42
8.3. Experimental murine intestinal anastomoses (IV) 44
8.4. Experimental piglet wounds (II) 44
68.5. Human skin fibroblast culture (III) 44
9. Discussion 45
9.1. Collagenases-1 and –3 and stromelysins-1 and –2 in cutaneous wound
healing (I, III) 45
9.1.Tissue inhibitors of matrix metalloproteinases-1, -2, -3 and –4 in cutaneous 
wound healing (II, V) 49
9.2. Collagenases-1 and –3, stromelysins-1 and –2, matrilysin, and macrophage
metalloelastase in inflammatory bowel diseases (I, IV) 50
9.2.  Tissue inhibitors of matrix metalloproteinases-1 and -3 in  inflammatory
bowel diseases (I, IV) 53
9.5. Matrix metalloproteinases in animal models (II, IV) 53
10. Conclusions 55
11. Acknowledgements 56
12. References 58
71.  LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following publications:
I  Saarialho-Kere U, Vaalamo M, Puolakkainen P, Airola K, Parks WC, and Karjalainen-Lindsberg
M-L: Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers.
Am  J  Pathol 1996, 148: 519-526
II  Vaalamo M, Weckroth M, Puolakkainen P, Saarinen P, Kere J, Lauharanta J, and Saarialho-Kere
U: Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing
cutaneous wounds. Br J Dermatol 1996, 135:52-59
III  Vaalamo M, Mattila L, Johansson N, Karjalainen-Lindsberg M-L, Kariniemi A-L, Kähäri V-M
and Saarialho-Kere U:  Distinct populations of stromal cells express collagenase-3 (MMP-13) and
collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. J Invest Dermatol
1997, 109: 96-101
IV Vaalamo M, Karjalainen-Lindsberg M-L, Puolakkainen P, Kere J, Saarialho-Kere U:  Distinct
expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage
metalloelastase (MMP-12) and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal
ulcerations. Am J Pathol 1998, 152: 1005-1014
V Vaalamo M, Leivo T, Saarialho-Kere U: Differential expression of tissue inhibitors of
metalloproteinases (TIMP-1, -2, -3 and -4) in normal and aberrant wound healing. Human Pathol
1999, 30: 795-802
The publications are referred to in the text by their Roman numerals
82.  ABBREVIATIONS
AP-1 activating protein-1
BPAG bullous pemphigoid antigen
bFGF basic fibroblast growth factor
BM basement membrane
cDNA complementary deoxyribonucleic acid
DNA deoxyribonucleic acid
ECM extracellular matrix
EGF epidermal growth factor
ETS E26 transformation specific
HD-1 hemidesmosomal protein-1
IBD inflammatory bowel disease
IFAP300 intermediate filament associated protein 300
IGFBP insulin-like growth factor binding protein
IL interleukin
kDa kilodalton
KGF keratinocyte growth factor
MBP myelin basic protein
MMP matrix metalloproteinase
mRNA messenger ribonucleic acid
MT-MMP membrane-type metalloproteinase
PA plasminogen activator
PEA-3 polyoma enhancer activator-3
PCR polymerase chain reaction
PDGF platelet-derived growth factor
PMA phorbol 12-myristate 13-acetate
RNA ribonucleic acid
SPARC secreted protein acidic and rich in cysteine
TGF-α transforming growth factor-alfa
TGF-β transforming growth factor-beta
TIMP tissue inhibitor of  metalloproteinases
TNF-α tumor necrosis factor-alfa
tPA tissue-type plasminogen activator
uPA urokinase-type plasminogen activator
VEGF vascular endothelial growth factor
93. ABSTRACT
Matrix metalloproteinases (MMPs) are a group of proteolytic enzymes, that are collectively able to
degrade most, if not all, components of the extracellular matrix (ECM). This capacity is needed in
conditions with active remodeling of the connective tissue, such as fetal development, cancer
invasion and metastasis, as well as wound healing. In this study, the expression patterns of MMPs
and tissue inhibitors of metalloproteinases (TIMPs) were investigated in normally healing and
chronic cutaneous wounds, and in chronic intestinal ulcerations. The principal methods used were in
situ hybridization and immunohistochemistry.
In normally healing cutaneous wounds, the migrating front of keratinocytes expressed collagenase-1
and stromelysin-2. These enzymes were induced within 1-3 days after wounding, and the expression
was turned off after complete re-epithelialization. Stromelysin-1 was expressed by proliferative
keratinocytes on a newly formed basement membrane. Collagenase-1 and stromelysins-1 and -2
were expressed in the same spatial pattern also in the epithelium of chronic ulcers. In addition to
epithelial events, MMPs were involved in stromal remodeling. In both normally healing and chronic
wounds, the expression of collagenase-1 by stromal cells was a constant finding. Contrasting this,
collagenase-3 was only expressed in fibrotic areas of chronic ulcers, but not in acute wounds.
Stromelysin-1 mRNA was detected in the stroma in both acute and chronic wound samples.
TIMPs-1 and –3 were expressed by basal, proliferating keratinocytes in normally healing, but not in
chronic cutaneous wounds, suggesting imbalance of the MMPs and their inhibitors in chronic
ulcers. TIMPs-1 and -3 were also expressed by stromal cells in both wound types. TIMP-2 protein
was detected in wound stroma, and particularly in acute wounds, surrounding the migrating front of
keratinocytes. TIMP-4 protein was only found in few stromal cells in chronic ulcers.
No collagenase-1 nor stromelysin-1 mRNAs were detected in intestinal epithelium. Instead,
matrilysin and stromelysin-2 were expressed by migrating intestinal epithelial cells. Collagenase-1,
collagenase-3 and stromelysin-1 were abundantly expressed by activated fibroblast-like cells
beneath erosions or ulcerations in inflammatory bowel disease (IBD). Macrophage metalloelastase
mRNA was detected in macrophages within the inflammatory infiltrate, and underneath the
shedding epithelium. TIMPs-1 and –3 mRNAs were detected in the stroma of IBD lesions as well,
but, as in chronic cutaneous wounds, the epithelium remained negative.
In conclusion, successful wound healing is accompanied by tightly scheduled expression of
metalloproteinases and their inhibitors. Their imbalance may delay wound healing and result in
chronic ulcers. MMPs and TIMPs are also involved in both tissue destruction and mucosal
reparative processes during the course of inflammatory bowel diseases.
10
4.  INTRODUCTION
Wound healing is a process that results in restoration of the injured tissue. It involves re-
epithelialization, granulation tissue formation and connective tissue remodeling. These events
require controlled lysis of the extracellular matrix, important mediators of which are matrix
metalloproteinases (matrixins, MMPs). MMPs comprise a group of enzymes that collectively are
able to degrade most, if not all, components of the extracellular matrix (ECM). These enzymes are
divided into subfamilies of collagenases, stromelysins, gelatinases, and MT-MMPs, based on their
structure and substrate specificities. The expression of MMPs is controlled by cytokines, growth
factors, oncogenes, and changes in the cell-cell and cell-matrix interactions. In the skin, the main
cell types expressing these enzymes are keratinocytes, fibroblasts, macrophages, and endothelial
cells. Tissue inhibitors of metalloproteinases (TIMPs) -1, -2, -3 and -4, are the most important
inhibitors of MMPs, whose activities are required not only to prevent excessive proteolysis of
tissues but also to regulate e.g. cell proliferation and angiogenesis. MMPs, controlled by their
inhibitors, are involved in physiological processes such as reproduction and fetal development. An
imbalance between MMPs and TIMPs has been implicated in abnormal tissue degradation leading
to chronic wounds as well as cancer invasion and metastasis.
In this study, we investigated the cellular origin, and the temporal expression patterns of
collagenases-1 and –3, stromelysins-1 and –2, matrilysin and macrophage metalloelastase in
normally healing and chronic wounds of the skin. Furthermore, MMP-expression profiles in
chronic, erosive and/or ulcerative lesions caused by inflammatory bowel disease (IBD),
multifactorial disorders of the intestine, were studied. The inhibitors of MMPs, TIMPs, as well as
various ECM proteins, were also examined in lesions of the skin and the intestine.
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5.  REVIEW OF THE LITERATURE
5.1.  STRUCTURE OF THE SKIN AND GUT
Figure 1. Structure of the skin. Modified from Kariniemi & Kauppinen, 1989
5.1.1.  Epithelium
Epithelium is comprised of one or multiple layers of cells, that cover the exterior surfaces of the
body and line the internal body cavities and tubes. It also forms the secretory portion of the glands
and their ducts. The epithelium is multifunctional: an almost impermeable barrier as in the skin,
secretory as in the glands, or both secretory and absorptive as in the intestine.
Skin:
The stratified epithelial layer of the skin, the epidermis, forms a barrier to protect the individual
from water loss, entry of micro-organisms, and radiation. The main cell type of the epidermis is the
keratinocyte, which migrates from the basal layer outwards, and is ultimately sloughed from the
skin surface. Other cell types found in the epidermis are Langerhans cells, which have immunologic
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functions, melanocytes, which donate pigment to the keratinocytes, and Merkel cells. The layers of
epidermis differ from each other by the state of keratinocyte differentiation. In the basal cell layer
undifferentiated, proliferating cells lie on an intact basement membrane. Spinous layer and granular
layer are named after their microscopic appearance. Keratinocytes of the spinous layer synthesize
keratin peptides, while the cells in the granular layer contain granules of profilaggrin and lipid. The
transition zone where the cornified envelope is constructed, forms a region between the living and
the dead cells. The cornified cell marks the final point of keratinocyte differentiation. Almost 80%
of the corneocytes is keratin, but also remnants of organelles, melanin and membrane profiles are
found. (see Eckert et al, 1989; see Eady et al, 1998)
Intestine:
Unlike the epidermis, the epithelium of the intestinal tract is formed by a single layer of columnar
cells, that form glands, pits, villi or crypts, depending on the region of the gut. Five cell types are
present in the intestinal epithelium, namely absorptive cells enterocytes, mucus producing goblet
cells, secretory APUD cells, Paneth cells, and undifferentiated cells. Every 3-8 days, the epithelium
is renewed. This process begins in the proliferative zone, where the undifferentiated epithelial cells
differentiate and migrate towards the luminal surface to be sloughed off. (see Ross & Reith, 1985a;
see Graham et al, 1992).
5.1.2.  Basement membrane
 
Skin & Intestine:
Basement membranes are continuous sheets that separate layers of cells from the underlying
connective tissue. They are structurally rather similar in different organs. Basement membranes
provide means of support for cell layers, regulate cell attachment, growth and differentiation. They
also act as molecular sieves between tissue compartments, and are able to select certain cells for
passage through the BM. (see Yurchenko & Schnitty, 1990)
Basement membranes are formed from components produced by both epithelial and stromal cells.
These components include the network-forming type IV collagen and laminin-1, that are found in a
variety of basement membranes, including those under skin and intestinal epithelium (see van der
Rest & Garrone, 1991; Foidart et al, 1980; Grant & Leblond, 1988). In the small intestine, however,
laminin-1 and -2 are expressed reciprocally, the former as the villus-form, and the latter as the crypt-
form (see Beaulieu, 1999). Nidogen/entactin links type IV collagen and laminin-1 fibers and
anchors other molecules of the BM. Other components of the BM include heparan sulphate
proteoglycans such as perlecan that confer filtrating properties, SPARC (secreted protein acidic and
rich in cysteine) that appears essential during development and wound healing, and fibulins. (see
Yurchenko & Schnitty 1990; Yurchenko & O`Rear 1994; Uitto et al, 1995)
The hemidesmosomes are specialized junctional complexes, that contribute to epithelial cell
attachment to the underlying BM in epithelia of the skin, the cornea, parts of gastrointestinal and
respiratory tract, and the amnion. They are composed of plectin (McLean et al, 1996), bullous
pemphigoid antigen (BPAG) 1 (Stanley et al, 1988), HD1, intermediate filament associated protein
(IFAP) 300, bullous pemphigoid antigen 2 (BPAG2, type XVII collagen) (Giudice et al, 1992), and
α6β4 integrin (Stepp et al, 1990; Sonnenberg et al, 1991). Plectin and BPAG1 form the cytoplasmic
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plaque together with two less well characterized proteins called HD1 and IFAP 300 (see Borradori
& Sonnenberg, 1999). The β4 integrin subunit binds to plectin, which mediates the interaction
between the hemidesmosome and  the keratin cytoskeleton. Laminin-5 (Rousselle et al, 1991) binds
the transmembrane constituents α6β4 integrin, and possibly also BPAG2, and traverses through
lamina lucida to the lower portion of the BM. The connection to underlying stroma is mediated by
laminin-5 attachment to type VII collagen, which forms a component of anchoring fibrils and
extends to the papillary dermis. (see Burgeson & Christiano 1997; see Borradori & Sonnenberg,
1999)
The anchoring system of intestinal epithelial cells differs from that of the skin by the electron
microscopic absence of hemidesmosomes (Leivo et al, 1996). In the intestine, adhesion complex
components laminin-5 and type VII collagen are confined to surface epithelia, suggesting some sort
of an adhesion complex, while the epithelium of the crypts lacks these components (Leivo et al,
1996; Lohi et al, 1996; Orian-Rousseau et al, 1996).
5.1.3.  Connective tissue
The connective tissue is a supporting matrix, which also directs tissue development and interacts
with connective tissue cells. It is divided into two general subtypes. The loose connective tissue
contains aggregates of loosely arranged fibers and different cells, many of which participate in the
defense mechanism of the body. The dense connective tissue contains more numerous and thicker
fibers, but considerably fewer cells of chiefly one type, the fibroblast.
Connective tissue components
Fibrillar collagens types I and III, and type II in the bone and cartilage, are the most abundant
components of the connective tissue. Most of the collagens are synthesized by fibroblasts as
procollagen molecules (Prockop & Kivirikko, 1995), which are then processed in the extracellular
space. Nonfibrillar collagens form sheetlike structures, e.g. type IV collagen in the basement
membranes, or connect ECM components to collagen fibrils. (see van der Rest & Garrone, 1991)
The elasticity of the connective tissue is provided by the elastic fibers, complex structures that
contain their predominant protein elastin, microfibrillar proteins, and perhaps, proteoglycans.
Elastin endows the fibers with the characteristic property of elastic recoil. (see Mecham & Heuser,
1991)
Proteoglycans form the amorphous ground substance of the connective tissue. They are complex
molecules with a core protein and glycosaminoglycan side chains. Proteoglycans are found inside
cells, on the cell surface, and in the ECM. They may influence cell proliferation and adhesion, have
protease and antiprotease function, and act as polypeptide growth factors (see Wight et al, 1991; see
Pope et al, 1998).
Fibronectin is a cell interactive protein present in a variety of extracellular matrices. It is produced
by various cell types, and has the ability to bind to ECM macromolecules and to integrin receptors.
It is upregulated during e.g. wound healing when it facilitates cell adhesion and migration. (see
Yamada, 1991)
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Tenascin, SPARC (secreted protein acidic and rich in cysteine) and thrombospondin are anti-
adhesive ECM glycoproteins that modulate cell-matrix interactions. For example, tenascin inhibits
cell adhesion and spreading, and promotes cell rounding, SPARC has been shown to induce MMP
expression in fibroblasts, and thrombospondin promotes angiogenesis in vitro (Chiquet-Ehrismann
et al, 1989; Tremble et al, 1993; Nicosia & Tuszynski, 1994). These proteins are present in normal
ECM in faint amounts, but are greatly upregulated during morphogenesis and remodeling.
Interestingly, wounds in tenascin-C deficient mice heal normally (Forsberg et al, 1996), and wounds
in mice deficient in thrombospondin-2 appear to heal at an accelerated rate, but have an abnormal
granulation tissue (Kyriakides et al, 1999). (see Sage & Bornstein, 1991; see Lightner, 1994).
Connective tissue cells
Fibroblasts are the main cell type found in the connective tissue. Fibroblasts are largely responsible
for the production of extracellular fibers and the ground substance of connective tissue.
Myofibroblasts contain relatively large amounts of myofilaments, but differ from smooth muscle
cells by lacking the basal lamina. Mast cells occur in most tissues, but are particularly numerous in
skin, bronchus, nasal mucosa and gut. They contain granules with varying amounts of neutral
proteinases tryptase and chymase. Macrophages are cells of diverse functions, e.g. phagocytosis,
antigen presenting, and secretion of growth factors and proteinases. Plasma cells are derivatives of
B lymphocytes, which actively produce antibodies, and are especially numerous in the intestinal
lamina propria. Transient, blood-derived cells include neutrophils, eosinophils, monocytes and
lymphocytes. In addition, there may be adipocytes and undifferentiated mesenchymal cells. (See
Pope, 1998; see Ross & Reith, 1985b)
Integrins
Integrins are a group of receptors by which cells attach to surrounding matrix or other cells. They
are heterodimers consisting of α and β subunits, that traverse the cell membrane. At least 8 β- and
15 α-subunits form numerous combinations, currently more than 20, which are divided in
subgroups based on their β-subunit (see Table 1.) The major ligands for integrins are 1)
extracellular matrix proteins, e.g. collagens and fibronectin, and 2) cell surface molecules, e.g.
intracellular adhesion molecules. The integrins can often bind more than one ligand, and ligands can
in turn often recognize more than one integrin. The integrins do not act solely as a means of
attachment between cells and the matrix components, but are also able to mediate signals through
the cell membrane in either direction, and therefore regulate cell functions. (see Hynes, 1992; see
Petruzelli et al, 1999; see Giancotti & Ruoslahti, 1999).
Normal epidermis has a characteristic distribution of the integrins. The α6β4 integrin is a component
of the hemidesmosome and mediates attachment of the basal keratinocytes to the basement
membrane zone (see Yancey, 1995). α2β1 and α3β1 integrins locate at the latero-apical membrane of
the basal keratinocytes (Peltonen et al, 1989). In human small intestine, α6 and β1 subunits locate at
the base of all enterocytes, while α1, α2, and α3 subunits are expressed in distinctive crypt-villus
gradients, reflecting the proliferation-migration-differentiation cascade of the intestinal epithelial
cells (Beaulieu, 1992). The α2 and α3 subunits are expressed in basolateral aspects of the intestinal
cell, the former being predominant in the crypts, and the latter on the villi (Beaulieau, 1992). β4
subunit is found in the entire crypt-villus epithelium in the small intestine (see Beaulieau, 1999).
However, the alpha-beta association of these interin subunits has not been investigated (see
Beaulieau, 1999). In gastric mucosa, α3β1 and α6β4 integrins are expressed closely confined to BM
areas in parts of gastric pits and surface epithelium, whereas the α6β1 integrin is found throughout
the gastric epithelium (Virtanen et al, 1995).
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Table 1.  Integrin ligands
Integrin Ligands
β1 α1 collagens, laminin
α2 collagens, laminin
α3 fibronectin, laminin, collagens, laminin-5
α4 fibronectin, VCAM-1
α5 fibronectin
α6 laminin
α7 laminin
α8 osteopontin, vitronectin, fibronectin
α9 tenascin
αV fibronectin, osteopontin, vitronectin
β2 αL ICAM-1, ICAM-2, ICAM-3
αM C3b, fibrinogen, factor X, ICAM-1
αX C3b, fibrinogen
β3 αIIb fibronectin, fibrinogen, vWf, vitronectin, thrombospondin
αV osteopontin, collagens
β4 α6 laminin, laminin-5 (Niessen et al, 1994)
β5 αV fibronectin, vitronectin
β6 αV fibronectin, tenascin
β7 α4 fibronectin
αE E cadherin
β8 αV fibronectin, VCAM-1, laminin
Modified from Petruzelli et al, 1999 and Clark, 1995.  VCAM vascular cell
adhesion molecule; ICAM intracellular adhesion molecule; vWF von Willebrandt factor.
Skin:
The connective tissue of the skin, the dermis, is divided into the subepithelial papillary dermis of the
loose connective tissue (1/10), and the reticular layer of thick collagen bundles (9/10), which lies on
adipose tissue. The papillary dermis contains a rich supply of blood vessels that penetrate from the
deeper layers. Dermal matrix consists mainly (75% of its dry weight) of fibrillar type I collagen
(>70%) and type III collagen (15%), which provide the skin with tensile strength. The reticular
dermis contains the skin appendices hair follicles, eccrine and apocrine sweat glands, and sebaceous
glands, ducts of which extend to the epidermis. (see Pope, 1998)
Intestine:
The intestine is divided in the following layers: 1) the mucosa, that consists of epithelium, basement
membrane, lamina propria, and muscularis mucosa, 2) the submucosa, 3) the muscularis propria,
and 4) the serosa which forms the outside cover of the intestine. The lamina propria is a loose
connective tissue composed mainly of collagens types I, III, and V, and elastin. It has a network of
capillaries and lymphatics and numerous mesenchymal as well as inflammatory cells, which act in
challenging and destroying antigens and other foreign substances such as bacteria. The lamina
propria is separated from the submucosa by a thin layer of smooth muscle cells named muscularis
mucosa. The submucosa is a loose connective tissue with many vessels. The collagen content differs
from that of the skin by a larger amount of type III (20 %) and type V (12%) collagens, while 68 %
is type I collagen. Another characteristic feature is the activity of the smooth muscle cells in the
maintenance of the extracellular matrix of the intestinal wall. (see Ross & Reith, 1985a; see Graham
et al, 1992)
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Figure 2. Layers of the intestinal wall. Modified from Graham et al, 1992.
5.2.  WOUND HEALING
Wound healing is a complex process during which the injured tissue, e.g. skin or intestinal wall, is
repaired. It involves inflammation, re-epithelialization, neoangiogenesis, and connective tissue cell
activation with subsequent ECM degradation and resynthesis. All these processes are regulated by
cell-ECM interactions and by various cytokines and growth factors. Injury initiates the rapid onset
of a vigorous, multicellular wound healing reaction, which then gradually, during following weeks
or months, proceeds towards a rather acellular scar.
5.2.1.  Cutaneous wound healing
Re-epithelialization
Keratinocyte migration is needed for the wound to be recovered by the epithelium. Migration over
the provisional matrix begins within hours after wounding. The migratory keratinocytes originate
not only from the cut edge of the wound, but also from the skin appendages. Platelets release growth
factors such as PDGF, TGF-β, and EGF-like growth factors from their α-granules, and initiate
coagulation, which results in the formation of a provisional matrix. This matrix consists mainly of
fibrin and fibronectin and provides a surface on which epidermal cells migrate (Clark et al, 1982).
Wound area is rich in cytokines and growth factors, which may induce migration (see Slavin, 1996).
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KGF and EGF, for example, are abundant in healing wounds, and induce keratinocyte migration and
proliferation (Werner et al, 1992; Tsuboi et al, 1993; see Clark, 1995). An alternate stimulus for
migration is provided by contact of the keratinocytes with fibronectin, fibrin and vitronectin via
integrins. In wounded epidermis, integrins α3β1, α5β1, and αvβ5 appear on greater amounts on basal
and suprabasal keratinocytes, possibly mediating migration over the provisional matrix (Kim et al,
1992; Larjava et al, 1993a; Cavani et al, 1993; Juhasz et al, 1993; Kim et al, 1994). While actively
migrating, the keratinocytes produce the BM component laminin-5, and proteases e.g. collagenase-1
and uPA (Grøndahl-Hansen et al, 1988; Larjava et al, 1993a; Saarialho-Kere et al, 1993b).
Proliferation of the wound edge keratinocytes begins within two days after injury, possibly induced
by altered growth factor/growth factor receptor profiles. A relatively late event in human wound
healing is the expression of fibronectin and tenascin binding integrin αvβ6 by the keratinocytes
covering the wound bed (Haapasalmi et al, 1996). (see Clark, 1995; see Woodley, 1996)
Figure 3.  Dermal wound repair. Modified from Robbins et al, 1989a.
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Stromal remodeling:
1. The inflammatory phase
The inflammatory phase of wound healing is characterized by increased vascular permeability, local
release of cytokines and growth factors, and activation of migrating cells. Neutrophils are the first
cells to arrive to clear the injured area from bacteria. Cytokines released by platelets act as
chemotactic agents for neutrophils and macrophages, which in turn secrete e.g. TNF-α and IL-1,
(see Steed, 1997; see Singer & Clark 1999). Influx and activation of macrophages is critical to the
wound healing process. They participate in matrix synthesis and degradation, and are able to
mediate angiogenesis and fibroplasia as well as activate e.g. lymphocytes via excretion of cytokines.
(see Clark, 1995)
2. The proliferative phase
During the proliferative phase, fibroblast-like cells and endothelial cells become activated and
migrate from surrounding tissues and closeby venules, respectively, to the wound area. The
provisional matrix serves as a reservoire for various cytokines, directs signals to the cells via
integrin receptors, and its collagen and fibronectin provide scaffolding for contact guidance for
migrating cells. While migrating, the fibroblasts use integrins to attach to provisional matrix
fibronectin and fibrinogen (Huhtala et al, 1995; Gailit & Clark, 1996). Mesenchymal cell activation
appears to be the rate-limiting step of the beginning of granulation tissue formation around three
days after injury (McClain et al, 1996). Their activation and chemotaxis is mediated mainly via
cytokines such as PDGF and TGF-β, released from α-granules of platelets and produced by
activated macrophages. After migration to the injured area, fibroblasts together with macrophages
begin to produce proteins for the ECM, including glycosaminoglycans, proteoglycans, and other
proteins such as SPARC, tenascin and thrombospondin. Newly formed blood vessels provide for the
nutrient and oxygen supplies. VEGF together with bFGF may enhance neovascularization (see
Slavin et al, 1996). Collagen synthesis by fibroblasts begins in the deep dermis during the first days
after wounding (Scharffetter et al, 1989; Petri et al, 1997), possibly induced by TGF-β, which is
abundantly expressed in wounds (Quaglino, 1990; Quaglino, 1991; see Raghow, 1991).
Macrophage products TNF-α and IL-1 have an opposite effect and reduce collagen production by
experimental granulation tissue fibroblasts (Rapala et al, 1996; Rapala, 1997; see Steed, 1997).
Interestingly, low concentration of PDGF-AB up-regulates collagen synthesis, while high
concentration down-regulates it (Lepistö et al, 1995). During the first days after wounding, collagen
type III is the main fibrillar collagen produced, and is later gradually replaced by collagen type I.
Transformation of the granulation tissue fibroblasts into myofibroblasts results in the contraction of
the wound with subsequent diminishing of the wound area. This may be mediated by TGF-β, which
has been shown to enhance contraction of collagen gels by dermal fibroblasts (Reed et al, 1994;
Montesano et al, 1988). Furthermore, the involvement of integrin α2β1 in wound contraction has
been suggested (Schiro et al, 1991). (see Gailit & Clark, 1994; see Clark, 1995; see Witte & Barbul,
1997)
3. The remodeling phase
Remodeling is the longest phase of wound healing, lasting from weeks to months. During this
phase, the neovascularization recedes and the loose provisional matrix is gradually replaced by
collagen fibers, which are thereafter rearranged by proteolysis and reproduction, to provide the scar
with tensile strength. While the provisional matrix collagen is almost exclusively of type III, during
the course of wound healing it is degraded by collagenase activity, and replaced by collagen type I,
the main collagen of the mature scar. The maturation of the scar tissue is completed in about one
year. Despite long-lasting remodeling of the matrix, the wound area never reaches the level of
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organization of normal fibrillar collagens. The resulting scar tissue gains maximum 80 % of the
tensile strength of normal skin. (see Clark, 1995; see Witte & Barbul, 1997; see Gailit & Clark,
1994)
Figure 4. Intestinal wound repair. Modified from Graham et al, 1992.
5.2.2. Intestinal wound healing
In the intestine, the healing process depends on how deep the injury penetrates. 1) Superficial
damage confined to the epithelial layer results in rapid covering of the wound by epithelial cells
without inflammation and scar formation. This process called restitution begins shortly after injury
by shedding of the damaged cells, which then form a cover for the restituting epithelium. The viable
epithelial cells become flattened and start to migrate on the basement membrane until the cells
touch and form new tight junctions. Restitution is completed within hours, and differs from normal
epithelial migration by the lack of mitosis. (for review, see Lacy, 1988 and Wilson & Gibson, 1997)
2) Healing of mucosal lesions, erosions, involves inflammation and proliferation, but leaves no
clinical or histological evidence of scar. Thus, the mucosa appears to heal itself by reconstitution
and regeneration, and not by repair. 3) Healing of deeper lesions involving the submucosal layers of
the intestine, intestinal ulcers, varies according to the duration of the lesion. Acute intestinal ulcers
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often have minimal fibrotic response, and resorption of the scar tissue occurs. In chronic intestinal
ulcers, there is significant fibrosis in the deeper layers of the intestine, which results in
morphological changes such as stricture formation. 4) Surgical intervention results in incisional or
anastomotic healing. This healing process is initiated by short-term, full-thickness injury to the
intestine. It mimics that of healing dermal wounds with phases of hemostasis, inflammation,
proliferation and remodeling. A major difference is the role of smooth muscle cells instead of
fibroblasts in collagen production. Growth factors may, as well, serve varying roles in wound
healing in different organs; TGF-β, for example, enhances collagen production in skin fibroblasts,
but suppresses it in colonic fibroblasts (Martens et al, 1992). Growth factors such as EGF and TGF-
α are vital in epithelial migration, while bFGF and VEGF stimulate angiogenesis during intestinal
wound healing (see Jones et al, 1999). In the colon, the healing process is slower compared to the
small intestine (see Brasken, 1991). Colonic anastomoses have prolonged presence of inflammatory
reaction with polymorphonuclear leukocytes, and a slightly poorer vascularity during the first
postoperative days. Also, mucosal repair is slower in the colon than in the small intestine. Similarly
as in the skin wounds, healing intestinal anastomoses never gain the breaking strength of normal
intestine. (see Graham et al, 1992; see Mast, 1997)
5.3.  CHRONIC CUTANEOUS  WOUNDS
When a wound fails to heal, it results in a chronic, nonhealing ulcer. The chronic ulcer usually
develops medially above the malleoli as an irregular craggy area, and is often complicated by
infections. Recurrency rate of a chronic leg ulcer is high. Leg ulcers are a common problem of the
elderly, with e.g. 2% prevalence in  Swedish population aged 50-89 years (Nelzen et al, 1996). The
most common cause of a leg ulcer is chronic venous insufficiency (80-90%), followed by arterial
disease and diabetic neuropathy (Baker et al, 1992). Other causes include vasculitis, malignancies,
bacterial infections and pyoderma gangrenosum. Histologically, a venous ulcer is characterized by a
discontinuous epithelium in the wound margin, the ulcer base being covered by fibrinous exudate
with polymorphonuclear leukocytes. The underlying dermis contains numerous blood vessels
surrounded by fibrin cuffs, and the remainder of the dermis consists of fibrous tissue with a variable
number of inflammatory cells (Herrick et al, 1992). Extravasation of the red blood cells results in
purpura as well as collections of hemosiderin and melanin. Prolonged presence of ECM molecules
such as fibronectin, tenascin and chondroitin sulphate, and a greater number of B-cells and plasma
cells is detected in chronic ulcers, compared to acute wounds (Loots et al, 1998). No differences in
keratinocyte proliferation rates between normally healing and chronic wounds have been detected
(Andriessen et al, 1995). Factors contributing to poor healing may be e.g. the following: 1)
Keratinocytes may fail to migrate across the wound bed (see Falanga et al, 1994). 2) Fibrin cuffs
surrounding the blood vessels may bind growth factors and proteins, and impede oxygenation and
growth factor transportation to the wound area (Herrick et al, 1992; Highley et al, 1995). 3) Hypoxia
may stimulate the fibrotic response and hence interfere with proper tissue repair. (see Ferguson and
Leigh, 1998) 4) Excessive proteolysis may interfere with proper wound healing e.g. by degrading
provisional matrices needed for cell migration or by inactivating growth factors (Grinnell et al,
1992). 5) Polymicrobial aerobic/anaerobic flora complicating all leg ulcers may delay the healing
process (Dagher et al, 1978; Brook & Frazier, 1998). Thus, the pathogenesis of chronic wounds is
multifactorial, and one of the reasons for impaired wound healing may be altered balance of MMPs
and their inhibitors, TIMPs. (see Ferguson and Leigh, 1998; see Falanga et al, 1994)
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5.4.  INFLAMMATORY BOWEL DISEASE
Crohn´s disease and ulcerative colitis are chronic, inflammatory diseases of the gastrointestinal
tract. They are sometimes associated with extraintestinal manifestations, e.g. uveitis, ankylosing
spondylitis and skin lesions. Their origin is unknown, yet genetic predisposition, immunologic
mechanisms, and environmental factors such as changes in the bacterial flora of the intestine and
cigarette smoking, have been suspected as contributors to their pathogenesis. The global prevalence
of these diseases is generally estimated to be greater than 1 per 500 inhabitants in Western
countries, and most studies find ulcerative colitis to be more frequent than Crohn`s disease. (see
Robbins et al, 1989b; see Fiocchi 1998; see Hugot et al, 1999).
Clinical manifestations of Crohn`s disease are variable. The beginning of the disease is
characterized by attacks of fever, diarrhea and abdominal pain, which are spaced by asymptomatic
periods. The inflammation in Crohn`s disease involves any level of the gastrointestinal tract, and
leads to progressive damage. It presents with patchy, sharply demarcated inflammation of
noncaseating granulomas and neutrophil abcesses affecting all layers of the intestine. Diseased
muscularis mucosa and submucosa are characterized by lymphoid aggregates, increase in the
number of smooth muscle cells, and presence of fragmented, disorganized collagen fibers. Deep-
seated inflammation leads to deep ulcerations and complications typical of Crohn`s disease, namely
fibrosis and fistula formation. (see Robbins et al, 1989b; see Podolsky, 1991; See Graham et al,
1992)
Ulcerative colitis presents as a relapsing disorder with attacks of bloody mucoid diarrhea followed
by asymptomatic periods of varying lengths. The most feared complications of this disease are
fulminant colitis and cancer. Ulcerative colitis affects the mucosal layers of the colon and rectum,
invariably beginning in the rectum and gradually extending along the colon in a retrograde fashion.
Histologically, it is characterized by continuous inflammation with an infiltrate of mononuclear
cells, neutrophils, eosinophils and mast cells. Small mucosal hemorrhages may develop suppurative
centers, crypt abcesses, which may give rise to small ulcerations, or rupture to underlying tissue.
The inflammation in ulcerative colitis is more superficial than in Crohn`s disease, leads to ulcers
that seldom extend beyond the submucosa, and to an increased turnover and depletion of the ECM.
(see Robbins et al, 1989b; see Podolsky, 1991; See Graham et al, 1992)
5.5.  MATRIX DEGRADING ENZYMES
Tissue remodeling is frequently encountered in physiological and pathological states such as wound
healing, fetal development, joint inflammation, and cancer invasion and metastasis. Proteolytic
activity of different cell types is essential for these conditions. The main groups of ECM-degrading
proteinases are metalloproteinases, serine proteinases, and cysteine proteinases as divided upon their
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active center. The serine proteinases, tissue-type plasminogen activator (tPA) and urokinase-type
plasminogen activator (uPA), convert the zymogen plasminogen into plasmin, which can degrade
several ECM components and activate proforms of certain matrix metalloproteinases. UPA is also
able to degrade at least fibronectin, and activate gelatinase A (Keski-Oja et al, 1992). Cysteine
proteinases cathepsin B, D, G, H, L and N are lysosomal in origin, but released into the ECM in
some pathological conditions. The cysteine proteinase cathepsin G may contribute to ECM
remodeling by activating latent collagenase-1. (See Saksela and Rifkin, 1988; Mignatti and Rifkin,
1993; Mauch et al, 1994)
5.5.1.  Matrix metalloproteinases
Matrix metalloproteinases (matrixins, MMPs) are a family of structurally related, zinc-dependent
endopeptidases. The first member of this family was found attacking triple-helical collagen in
resorbing tadpole tails in metamorphosis (Gross & Lapiere, 1962). Today, at least 19 MMPs have
been found (Table 2). They have been implicated in numerous physiological processes, e.g.
reproduction, fetal development and wound healing (Stricklin et al, 1993; Stricklin et al, 1994a;
Stricklin et al, 1994b; Rodgers et al, 1994; Inoue et al, 1995; Airola et al, 1998), and in pathological
processes such as cancer cell invasion and metastasis, tissue degradation during inflammatory
processes of various organs, lung diseases, multiple sclerosis, atherosclerosis and blistering skin
diseases (see O`Connor & FitzGerald, 1994; see Cawston & Billington, 1996; see Jones & Walker,
1997; see Chandler et al, 1997; Knox et al, 1997; see Kähäri & Saarialho-Kere, 1997; Uitto et al,
1998). The family of the MMPs consists of collagenases, gelatinases, stromelysins, MT-MMPs, and
others, as divided by their structure and function (Table 2). As a group these enzymes can in vitro
degrade essentially all components of the ECM.
There are some structural features common to all MMPs. All members of the family share the
propeptide domain that is lost upon activation, and the catalytic domain, which contains the zinc-
binding site (see Woessner 1991, see Birkedal-Hansen et al, 1993). The hinge-region marks the
transition to the COOH terminal domain. The hemopexin- or vitronectin-like COOH-terminal
domain is likely to play a role in encoding substrate specificity and belongs to all MMPs except for
matrilysin, which therefore is the smallest of the MMPs (see Birkedal-Hansen et al, 1993). In
collagenase, for example, deletion of the C-terminal domain prevents it from cleaving native
collagen (Murphy et al, 1992). The gelatinases possess an insert within the catalytic domain, that
provides the enzymes with gelatin-binding properties (Goldberg et al, 1989). The transmembrane
domain of the membrane-type MMPs localizes their action to the cell surface. The recently cloned
MMP-23 exhibits sequence similarity with other MMPs, but displays a different domain structure,
lacking a recognizable signal sequence and having short prodomain, and C-terminal domain with no
hemopexin-like repeats (Velasco et al, 1999). (see Seiki, 1999)
5.5.1.1.  Collagenases
Collagenases (collagenases-1, -2 and -3; MMPs-1, -8 and -13) are named after their unique capacity
to degrade fibrillar collagen types I, II, III, V and IX. The fibrillar collagens are cleaved at a specific
site to yield N-terminal ¾ and C-terminal ¼ fragments, which denature to gelatin at room
temperature. Collagenase-1 degrades preferentially type III collagen, while collagenase-2 has
Table 2. Matrix metalloproteinases, their substrates, exogenous activators, and activating capacity
Enzyme Substrates Activated by Activator of
Collagenases
Collagenase-1 (MMP-1) Collagen I, II, III (III>I), VII, VIII, X, gelatin, aggrecan, versican,
proteoglycan link protein, L-selectin, entactin, tenascin, serpins, α2-
macroglobulin, TNF precursor, MBP, IGFBP-3
MMP-3, -10, plasmin, kallikrein,
chymase
MMP-2
Collagenase-2 (MMP-8) Collagen I, II, III (I>III), VII, VIII, X, gelatin, aggrecan, fibronectin,
laminin, serpins, α2-macroglobulin
MMP-3, -10, plasmin ND
Collagenase-3 (MMP-13) Collagen I, II, III (II>I or III), IV, IX, X, XIV, gelatin, aggrecan, perlecan,
fibronectin, laminin, tenascin, fibrillin*, SPARC**, serpins, PAI
MMP-2,-3, -10,-14, -15, plasmin MMP-2, -9
Gelatinases
Gelatinase A, 72 kDa (MMP-2) Gelatin, collagen  I, IV, V, VII, X, XI, XIV, aggrecan, versican,
proteoglycan link protein, fibronectin, laminin, laminin-5 (Giannelli et al,
1997), tenascin, fibrillin*, SPARC**, elastin, vitronectin, α2-
macroglobulin, TNF precursor, MBP, IGFBP-3
MMP-1, -7, -13, -14, -15, -16, -24 MMP-9, -13
Gelatinase B, 92 kDa (MMP-9) Gelatin, collagen  IV, V, VII, X, XIV, aggrecan, versican, nidogen,
proteoglycan link protein, fibronectin, fibrillin*, SPARC **, entactin,
elastin, vitronectin, α1-antitrypsin, α2-macroglobulin, TNF precursor,
MBP, angiostatin
MMP-2, -3, -13, plasmin ND
Stromelysins
Stromelysin-1 (MMP-3) Collagen  III, IV, V, IX, X, gelatin, versican, nidogen, aggrecan, perlecan,
proteoglycan link protein, fibronectin, laminin, tenascin, fibrillin*,
SPARC**, entactin, elastin, TNF precursor, MBP, IGFBP-3
Plasmin, kallikrein, chymase,
tryptase, elastase, cathepsin G
MMP-1, -8, -9, -13
Stromelysin-2 (MMP-10) Collagen III, IV, V, gelatin, nidogen, aggrecan, proteoglycan link protein,
fibronectin, elastin
As stromelysin-1 MMP-1, -7, -8, -9,-13 (Nakamura et
al, 1998)
Stromelysin-3 (MMP-11) α1-proteinase inhibitor; weak activity on aggrecan, fibronectin, laminin Furin ND
Matrilysin (MMP-7) Collagen IV, gelatin, versican (Halpert et al, 1996), nidogen, aggrecan,
fibronectin, laminin, tenascin, SPARC**, elastin, vitronectin, MBP,
angiostatin
MMP-3, plasmin MMP-2
Metalloelastase (MMP-12) Collagen IV, gelatin, nidogen, aggrecan, fibronectin, laminin, fibrillin*,
elastin, vitronectin, α1-antitrypsin, TNF precursor, angiostatin
ND ND
Membrane-type MMPs
MT1-MMP (MMP-14) Collagen I, II, III, gelatin, nidogen, aggrecan, perlecan, fibronectin, laminin,
tenascin, vitronectin, fibrillin*
Plasmin, furin MMP-2, -13
MT2-MMP (MMP-15) Aggrecan, perlecan, fibronectin, laminin, nidogen, tenascin (d´Ortho 1997) ND MMP-2, -13
MT3-MMP (MMP-16) gelatin, casein (Shofuda et al, 1997) ND MMP-2
MT4-MMP (MMP-17) gelatin, TNF precursor (Wang et al, 1999) ND MMP-2
MT5-MMP (MMP-24) ND (Pei 1999; Llano et al, 1999) ND MMP-2
Other MMPs
MMP-18 & -19 gelatin (Sedlacek et al, 1998) Trypsin ND
Enamelysin (MMP-20) Amelogenin (Llano et al, 1997) ND ND
MMP-21 & -22 & -23 ND (Gururajan et al, 1999; Velasco et al, 1999) ND ND
Modified from Kähäri & Saarialho-Kere, 1997;  Chandler et al, 1997 and Imper & van Wart, 1998. *Ashworth et al, 1999.**Sasaki et al, 1997. ND not determined.
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preference for monomeric type I and II collagens (Welgus et al, 1981; Hasty et al, 1987).
Collagenase-3 is 10-fold more effective in degrading type II collagen, has a stronger gelatinolytic
activity than collagenase-1, and a broader substrate specificity than the other collagenases (see Table
2) (Knäuper et al, 1996). In vitro collagenase-1 is expressed in various normal cell types such as
keratinocytes, fibroblasts, endothelial cells, monocytes, macrophages, chondrocytes and osteoblasts
(see Birkedal-Hansen et al, 1993). Unlike collagenase-1, collagenase-2 expression has only been
detected in neutrophils, in chondrocytes in the presence of IL-1β, and in endothelial cells and
synovial fibroblasts (Cole et al, 1996; Hanemaaijer et al, 1997). Collagenase-3 was originally cloned
from breast cancer tissue (Freije et al, 1994) and its expression has been detected in developing
bone, in osteoarthritic cartilage and rheumatoid synovial membrane, in periodontitis, and in
malignancies such as melanoma and squamous cell carcinoma (Mitchell et al, 1996; Reboul et al,
1996; Johansson et al, 1997b; Johansson et al, 1997c; Uitto et al, 1998; Airola et al, 1999;
Johansson et al, 1999).
5.5.1.2.  Gelatinases
Gelatinases A and B (72 kDa and 92 kDa gelatinases; MMPs-2 and -9) cleave a number of peptide
bonds in denatured collagen to yield small peptides. Other substrates for the gelatinases include
types IV, V, VII and X collagen and elastin (see Kähäri and Saarialho-Kere, 1997). Gelatinase A has
been identified in skin fibroblasts, keratinocytes, chondrocytes, endothelial cells, monocytes,
osteoblasts and in a number of other normal and transformed cells (see Birkedal-Hansen et al,
1993). Gelatinase A knockout mice exhibit reduced angiogenesis, impaired primary tumor growth
and decreased experimental metastases of B16-BL6 melanoma and Lewis lung cell carcinoma cells
(Itoh et al, 1998). These mice suffer from a slight growing delay (Itoh et al, 1997). Gelatinase B is
produced by keratinocytes, monocytes, alveolar macrophages, polymorphonuclear leukocytes and
by numerous malignant cells but not by fibroblasts (see Birkedal-Hansen et al, 1993). Gelatinase B
knockout mice are viable, but have delayed chondrocyte apoptosis, vascularization and ossification,
resulting in abnormal lengthening of the skeletal growth plate (Vu et al, 1998). These mice do not
develop blisters in an experimental model for bullous pemphigoid, despite the presence of
neutrophils and antibodies to collagen type XVII (Liu et al, 1998), suggesting an important role for
this enzyme in the pathobiology of pemphigoid.
5.5.1.3.  Stromelysins
The stromelysin subgroup of MMPs includes stromelysins-1 (MMP-3) and -2 (MMP-10).
Matrilysin (MMP-7) and matrix metalloelastase (MMP-12) can be included in this group. These
enzymes have a broad substrate specificity, and they share the property of being able to activate
other MMPs. Stromelysin-3 (MMP-11) is distantly related to other stromelysins. It was initially
cloned from breast cancer tissue, and differs from other MMPs in that stromelysin-3 does not
exhibit proteolytic activity towards ECM components (Basset et al, 1990; see Basset et al, 1993).
The only known physiologic substrate for stromelysin-3 is α1-proteinase inhibitor (Pei et al, 1994).
Stromelysin-1 and stromelysin-2 are closely related structurally and have virtually identical
substrate specificities. In vitro they are able to degrade e.g. gelatin, fibronectin, types IV and V
collagens, elastin, and proteoglycan core proteins (Wilhelm et al, 1987; Murphy et al, 1991; see
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Chandler et al, 1997). In addition, stromelysin-1 cleaves TNF-α precursor, α1-proteinase inhibitor
and myelin basic protein (see Chandler at al, 1997). Stromelysin-1 is expressed by a diversity of
cells and tissues, e.g. fibroblasts, keratinocytes, chondrocytes, endothelial cells and macrophages.
Stromelysin-2 transcripts are expressed generally by normal or malignant cells of epithelial origin,
at lower levels than stromelysin-1, and no expression has been detected in skin fibroblasts in vivo.
Mice deficient in stromelysin-1 suffer from delayed healing of excisional wounds, due to impaired
wound contraction (Bullard et al, 1999). However, keratinocyte migration and epithelialization
proceed normally in these mice (Bullard et al, 1999). Stromelysin-1 deficiency does not affect
collagen-induced arthritis in mice (Mudgett et al, 1998). (see  Nagase, 1998)
Matrilysin, the smallest MMP due to the lack of hemopexin-domain, is often constitutively
expressed in glandular epithelial cells. For example, epithelial cells of sweat glands produce
matrilysin (Saarialho-Kere et al, 1995). It is also expressed by various cancer tissues and has been
linked with tumor progression (see Wilson et al, 1998). Matrilysin is able to degrade proteoglycans,
type IV and IX collagens, laminin, fibronectin, elastin, decorin, tenascin, globular domains of
procollagens I and III and β4 integrin subunit (von Bredow et al, 1997; see Wilson et al, 1998). It is
also able to activate procollagenase and process pro-TNFα, like stromelysin-1 (He et al, 1989,
Gearing et al,1994). Matrilysin may regulate new blood vessel formation by cleaving plasminogen
and generating angiostatin molecules (Patterson & Sang, 1997) and is likely to participate in the
degradation of ECM in osteoarthritis (Ohta et al, 1998). Intestinal tumorigenesis is suppressed in
mice lacking matrilysin (Wilson et al, 1997).
Human macrophage metalloelastase (HME) was initially found in alveolar macrophages of cigarette
smokers (Shapiro et al, 1993). It is expressed in macrophages and the stromal cells of placenta
(Belaaouaj et al, 1995) as well as in macrophage-like cells in breast cancer tissue (Heppner et al,
1996). Its substrates include elastin, type IV collagen, laminin, fibronectin, vitronectin and heparan
and chondroitin sulphates, and it is able to process TNF-α precursor and generate angiostatin
(Chandler et al, 1996; Gronski et al, 1997, Dong et al, 1997). HME participates in the degradation
of elastic fibers at least in aneurysm formation, where it has been detected together with matrilysin,
and in the pathogenesis of emphysema (Halpert et al, 1997; Hautamäki et al, 1997). Furthermore,
HME is involved in the pathogenesis of skin diseases with elastic tissue abnormalities (Vaalamo et
al, 1999; Saarialho-Kere et al, 1999). Mice deficient in HME undergo normal fetal and postnatal
development without inflammatory stress (Hautamäki et al, 1997). These mice have impaired
macrophage mediated proteolysis and matrix invasion (Shipley et al, 1996), increased numbers of
macrophages in their lungs, and they do not develop emphysema in response to long-term exposure
to cigarette smoke, unlike the wild-type mice (Hautamäki et al, 1997).
5.5.1.4.  Membrane-type metalloproteinases
Membrane-type metalloproteinases (MT-MMPs-1, -2, -3, -4, and -5; MMPs-14, -15, -16, -17, and -
24) are bound to the cell membrane, and take part in the activation of other MMPs besides their
ECM-degrading activities (see Knäuper and Murphy, 1998). Maturation of the pro-form of at least
MT1-MMP is regulated by an intracellular, furin-dependent pathway (Pei & Weiss, 1996; Sato et al,
1996). Extracellularly this enzyme can be activated by plasmin (Okumura et al, 1997). MT1-MMP
was cloned as an activator of 72kDa progelatinase (Sato et al, 1994). It  is expressed in lung, breast,
colon, gastric, and head and neck cancers by stromal or cancer cells (Nomura et al, 1995; Okada et
al, 1995; Polette et al, 1996). MT1-MMP is able to degrade fibrillar collagens type I, II and III,
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gelatin, proteoglycan, fibronectin, vitronectin and laminin-1 (Ohuchi et al, 1997). Mice deficient in
MT1-MMP suffer from ablation of collagenolytic activity, which leads to dwarfism, osteopenia,
arthritis and connective tissue disease (Holmbeck et al, 1999). These mice are viable, but their
mortality is increased.  Like MT1-MMP, MT2-MMP, cloned from placenta cDNA library, is able to
process progelatinase A into active form and shares also the substrate specificity with MT1-MMP
(Takino et al, 1995; Pei et Weiss, 1996; d´Ortho et al, 1997). Expression of  MT3- and MT4-MMPs
has been found in various normal tissues by Northern analysis (Will et Hinzmann, 1995; Puente et
al, 1996). These enzymes are able to process progelatinase A and hydrolyze gelatin, and MT3-MMP
substrates include also casein, type III collagen, fibronectin, vitronectin, laminin-1, α1 proteinase
inhibitor, and α2 macroglobulin (Shofuda et al, 1997; Sedlacek et al, 1998; Shimata et al, 1999).
The recently cloned MT5-MMP is expressed at least during fetal development and in adult brain
tissue in mice as well as in human brain, kidney, pancreas, and lung (Pei, 1999; Llano et al, 1999).
MT5-MMP is able to activate progelatinase A, and is overexpressed in brain tumors thereby
facilitating tumor progression (Pei, 1999; Llano et al, 1999).
5.5.1.5. Other matrix metalloproteinases
MMP-18 was cloned from human mammary gland cDNA. It is expressed in a wide variety of
normal human tissues, and has closest identity with MMPs-1, -3, -10 and –11 (Cossins et al, 1996).
MMP-19 was cloned from liver cDNA library, but it turned out to be identical to MMP-18 (Pendás
et al, 1997). A novel collagenase, also named MMP-18 (Xenopus collagenase-4), was cloned from
metamorphosing Xenopus laevis tadpoles (Stolow et al, 1996). Enamelysin (MMP-20) was cloned
from odontoblasts, and is expressed in dental tissues, and degrades amelogenin (Llano et al, 1997).
MMPs-21 and -22 genes were isolated and linked to the Cdc2L locus on human chromosome
1p36.3. Their catalytic domains are most closely related to stromelysin-3, and they express multiple
mRNAs, some of which are derived in a tissue-specific manner by alternative spilicing (Gururajan
et al, 1998). Essentially identical to MMPs-21 and –22 is MMP-23, which was cloned from an
ovary cDNA library, and is expressed in testis, ovary, and prostate (Velasco et al, 1999).
5.5.2.  Regulation of the matrix metalloproteinases
In normal tissues, the degradation and synthesis of ECM components is in balance. To maintain this
steady state, there is a low basal level expression of certain MMPs, and the enzyme activity is
tightly controlled. Inflammatory cytokines, hormones, growth factors, and cell-cell and cell-matrix
interactions stimulate the expression of these enzymes through changes in transcription. Their
activity is regulated by local activators, e.g. plasmin, and the specific inhibitors of the MMPs,
TIMPs.
5.5.2.1.  Regulation at the transcriptional level
Most cell types do not store MMPs, therefore the enzymes are expressed when needed, following
certain signals. Generally the expression of MMPs can be stimulated by exogenous agents such as
growth factors and cytokines. However, there are exceptions: e.g. gelatinase A is constitutively
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expressed and responds poorly to common regulators, and within neutrophils, collagenase-2 is
stored in granules, from where it is instantly released without preceding synthesis of the protein (see
Birkedal-Hansen et al, 1993). Collagenase-2 expression by other cell types, such as chondrocytes,
endothelial cells or synovial fibroblasts, is inducible (Cole et al, 1996; Hanemaaijer et al, 1997). IL-
1, TNF-α, PDGF, and EGF stimulate expression of many MMPs via signals that depend, at least
partially, on the activating protein-1 (AP-1) binding site. Regulatory elements of MMPs contain this
site, except for gelatinase A and stromelysin-3. AP-1 site binds dimers of the Fos and Jun families
and takes part in the basal and induced transcription of the MMP-promoter. AP-1 is necessary but
not sufficient for transcriptional induction of MMPs in response to PMA (Auble & Brinckerhoff,
1991). Basal transcription as well as induction of MMPs rely on interaction and cooperation of  AP-
1 site with other cis-acting elements such as polyoma enhancer activator 3 (PEA3). Conserved
PEA3 elements that bind members of the E26 transformation specific (ETS) family of transcription
factors, are present in all but MMP-2 promoters. DNA binding and trans-activation capacity of both
AP-1 and ETS transcription factors are regulated by phosphorylation by mitogen activated protein
kinases (MAPKs). MAPKs are serine/threonine kinases that mediate signals from cell membrane
receptors triggered by growth factors, cytokines, hormones, and cell-cell and cell-matrix interactions
(see Westermarck & Kähäri, 1999). TGF-β, glucocorticoid hormones and retinoids are common
downregulators of the transcription of the MMPs. However, regulation of MMP-expression is very
cell type specific. TGF-β, for example, downregulates the expression of collagenase-1 and
gelatinases in fibroblasts but upregulates the expression of these enzymes in keratinocytes (Edwards
et al, 1987; Salo et al, 1991; Mauviel et al, 1996). (Woessner, 1991; see Benbow & Brinckerhoff,
1997).
In wound healing, cancer invasion and metastasis, and inflammation, the composition and
organisation of the ECM changes constantly. Integrin receptors mediate information of these
changes to cells through binding of different ECM component. The binding of certain ECM
components may result in increased expression of  MMPs. Antibodies to the fibronectin receptor
that block adhesion of the fibroblasts to fibronectin, induce collagenase-1 and stromelysin-1 (Werb
et al, 1989), and antibodies to β1 and β2 integrin subunits stimulate expression of  gelatinase B, but
not that of gelatinase A (Larjava et al, 1993b). Three-dimensional contact with collagen induces
collagenase expression in fibroblasts (Mauch et al, 1989). This stimulation may be mediated by
integrin receptors, since at least in osteogenic cell lines cultured within collagen gel, collagenase-1
expression is regulated by the collagen receptor α2β1 integrin (Riikonen et al, 1995). Not only
changes in the ECM, but also in the cell itself may induce MMP expression; morphological changes
in fibroblasts resulted in increased expression of collagenase-1 (Varedi et al, 1995). Increase in cell
density downregulates EGF-mediated induction of collagenase and stromelysin (Colige et al, 1992),
and mechanical injury resulted in increased expression of these enzymes in a cell line derived from
vascular smooth muscle (James et al, 1993), which provide other examples of regulation of the
MMPs by cell shape.
5.5.2.2.  Zymogen activation
Most metalloproteinases are secreted as inactive precursor forms. The proteolytic activation of these
zymogens takes place outside the cell, excluding furin-dependent intracellular activation of
stromelysin-3 and MT1-MMP (Pei & Weiss, 1995; Pei & Weiss, 1996; Sato et al, 1996). The
latency of MMPs is dependent on ”cysteine switch” formed by interaction of a conserved cysteine in
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the propeptide with the zinc in the highly conserved catalytic site blocking the access of the
substrate to the catalytic site (van Wart & Birkedal-Hansen, 1990). The catalytic site can be released
by agents that are able to dissociate the covalent bond between the cysteine and the catalytic zinc.
Organomercurials (APMA) and chaotropic agents can break the bond between cysteine and zinc. In
vivo the activation most likely proceeds by proteolysis. Enzymes such as trypsin, plasmin and
kallikrein process the proenzyme into active intermediate, which then autocatalytically cleaves itself
to permanently active form. MMPs of the stromelysin subgroup are able to ”superactivate” other
MMPs to fully active form. Activation of the MMPs by the membrane-bound MT-MMPs provide
mechanisms for directing proteolytic activation to focal areas in the pericellular place. (see
Woessner, 1991; see Murphy et al, 1999).
5.5.2.3.  Inhibition of the activity of the metalloproteinases
The activity of the metalloproteinases may be inhibited by synthetic or natural inhibitors. The
former include chelating agents such as EDTA and 1,10-phenanthroline, and inhibiting antibodies
while the latter include specific inhibitors of MMPs, tissue inhibitors of metalloproteinases
(TIMPs), and non-specific inhibitors, e.g. alpha 2-macroglobulin and alpha 1-antiprotease. Alpha 2-
macroglobulin is abundant throughout the body, and may be important in controlling overall
proteolytic activity. (see Birkedal-Hansen et al, 1993)
5.5.2.4.  Tissue inhibitors of the metalloproteinases (TIMPs)
Tissue inhibitors of metalloproteinases are a family of secretory proteins that are able to inhibit
matrix metalloproteinase activities through non-covalent binding of pre- or active forms of MMPs
at molar equivalence. By inhibiting MMPs, TIMPs may influence also MMP-mediated processes
such as processing of cytokines, degradation of growth factor binding proteins, and the release of
ECM-bound growth factors (Gearing et al, 1995; Chandler, 1996; Whitelock et al, 1996; Martin et
al; 1999). Up to date, a total of four TIMPs have been characterized, designated as TIMP-1, TIMP-
2, TIMP-3 and TIMP-4. Members of this family have been detected in most human tissues and body
fluids, and except for TIMP-3, they are present in a soluble form. (see Edwards et al, 1996; see
Gomez et al,1997)
TIMP-1 is the oldest of the TIMPs. Like TIMP-2, it is able to inhibit all MMPs. However, TIMP-1
preferentially inhibits the activity of collagenase-1, while TIMP-2 is a stronger inhibitor of
gelatinase A and B (Howard et al, 1991). TIMP-1 and TIMP-2 have been shown to inhibit tumour
growth and metastasis in animal and cell culture studies (see Gomez et al, 1997). The expression of
both TIMP-1 and –2  is induced in various cell lines and tissues. TIMP-2 forms a complex with
MT1-MMP and takes part in the activation of gelatinase A in low concentrations, while high
concentrations inhibit activation (Strongin et al, 1995; Butler et al, 1997).
Unlike other members of the TIMP-family, TIMP-3 is bound to the ECM (Leco et al, 1994), and has
the capacity to inhibit TNF-α converting enzyme (TACE; ADAM-17) (Amour et al, 1998).  It
inhibits collagenase-1, gelatinases A and B, and stromelysin-1 as efficiently as TIMP-1 (Apte et al.,
1995). By Northern analysis, it is expressed in breast carcinoma and in various normal adult tissues
(Urìa et al, 1994; Apte et al, 1994). In situ hybridization studies have shown TIMP-3 expression
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also during embryonic development, and in skin, mammary and colon cancers (Powe et al, 1997;
Airola et al, 1998). In the eye, TIMP-3 forms a component of the Bruch`s membrane (Fariss et al,
1997).
The fourth tissue inhibitor of metalloproteinases, TIMP-4 (Greene et al, 1996; Leco et al, 1997), is a
potent inhibitor of at least collagenase-1, gelatinases A and B, stromelysin-1 and matrilysin, but has
preference for matrilysin, and for gelatinase A similarly as TIMP-2 (Liu et al, 1997). By Northern
analysis, TIMP-4 is expressed in adult heart and in the kidney, placenta, colon, and testicles (Greene
et al, 1996), and has been shown to inhibit the invasion potential of breast cancer cells in vitro and
tumor growth and metastasis in nude mice in vivo (Wang et al, 1997).
The expression of TIMP-1 is upregulated by various growth factors and cytokines, e.g. TGF-β and
IL-1β. The bifunctional effect of TNF is of interest; low concentrations of TNF stimulate TIMP-1
production while high concentrations suppress it (Ito et al, 1990). TIMP-2 expression is largely
constitutive (DeClerk et al, 1994). In addition to regulation by cytokines, TIMP-3 expression is
controlled in a cell-cycle dependent manner in certain cell types, and may serve as a marker for
terminal differentiation (Wick et al, 1994).
Even though the best known physiological function for the TIMPs is their ability to regulate MMP-
mediated proteolysis of the ECM, a growing number of other tasks have been established. For
example, TIMP-1 was originally cloned on the basis of its erythroid-potentiating activity, and later
TIMP-2 was found to share this property (Gasson et al, 1985; Docherty et al, 1985; Stetler-
Stevenson et al, 1992). Both TIMP-1 and -2 are able to stimulate growth of various cell types,
including keratinocytes and fibroblasts (Bertaux et al, 1991; Hayakawa et al, 1992; Nemeth &
Goolsby, 1993; Hayakawa et al, 1994). Overexpression of TIMP-1 stimulates type IV collagen and
laminin expression in rat mammary carcinoma cells, but has no effect on the expression of 72kDa
gelatinase, stromelysin-1 or 92 kDa gelatinase (Yoshiji et al, 1998). Overexpression of TIMP-1 in
rat vascular smooth muscle cells has no effect on cell proliferation, while that of TIMP-2 causes a
dose-dependent reduction in proliferation (Baker et al, 1998). Overexpression of TIMP-3 induces
DNA synthesis and promotes cell death by apoptosis (Ahonen et al, 1998; Baker et al, 1998). TIMP-
3 induced cell death of at least human colon carcinoma cells is mediated by protection of the TNF-
α-receptors from proteolytic cleavage (Smith et al, 1997). TIMP-1 and TIMP-3 are also able to
inhibit angiogenesis by blocking endothelial cell response to angiogenic factors, and both TIMP-2
and TIMP-3 inhibit endothelial cell tube formation in vitro (Johnson et al, 1994; Anand-Apte et al,
1997).
5.6.  MATRIX METALLOPROTEINASES IN CUTANEOUS WOUND REPAIR
Proteolytic degradation of the ECM is needed during re-epithelialization and stromal cell migration,
neoangiogenesis and remodeling of the injured tissue. Because of their ECM degrading capacities,
MMPs are most probably involved in distinct phases of wound healing. They may be needed in
removal of devitalized tissue and remodeling of newly formed connective tissue, in keratinocyte
migration, angiogenesis, and processing of certain growth factors (see Kähäri and Saarialho-Kere,
1997). Not only the contribution of MMPs, but also of other proteinases, e.g. serine proteinases, has
been investigated in the context of wound healing. Plasminogen activation has been shown in
iatrogenic human wounds, with subsequent removal of fibrin-containing provisional matrix (Schäfer
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et al, 1994). The putative harmful effects of excess plasminogen activation on wound healing have
been demonstrated by comparing wound fluids from chronic and normally healing wounds
(Palolahti et al, 1993). A role for plasminogen activation in re-epithelialization has been suggested,
since uPA, uPA receptor and type-1 plasminogen activator inhibitor (PAI-1) are expressed by
keratinocytes during human and murine wound healing (Grøndal-Hansen et al, 1988; Rømer et al,
1991; Rømer et al, 1994). Furthermore, mice deficient in plasminogen suffer from severely impaired
wound healing, with disturbed re-epithelialization and resolution of the fibrin clot (Rømer et al,
1996).
Collagenase-1 is the most investigated MMP in tissue repair. It is expressed by migrating
keratinocytes in different types of ulcers: collagenase-1 mRNA and protein have been detected in
pyogenic granulomas, venous and decubitus ulcers (Saarialho-Kere et al, 1992; Saarialho-Kere et al,
1993b). Wound edge keratinocytes in normally healing human wounds express collagenase-1
mRNA and protein from day 1 until complete re-epithelialization (Inoue et al, 1995). Human burn
wound keratinocytes express collagenase-1 mRNA from day 2 (Stricklin et al, 1993), but no protein
has been detected in the epithelium of burn wounds (Stricklin et al, 1994a). The activity of
collagenase-1 reaches its maximum during the first days, and declines rapidly after re-
epithelialization of acute porcine wounds (Ågren et al, 1992). Expression of collagenase-1 may be
induced when disruption of the BM exposes the keratinocytes to the underlying matrix, that consists
largely of fibrin and fibronectin (Clark et al, 1982). TGF-β and TNF-α are upregulated in wounds,
and these growth factors stimulate expression of collagenase-1 at least in cultured keratinocytes,
thus they might also contribute to collagenase-1 expression in wound margins (see Clark, 1995;
Mauviel et al, 1996; Johansson et al, 1997a). The activity of collagenase-1 may be regulated by
TIMP-1. In human burn wounds their expression has been reported to co-localize (Stricklin et al,
1993) but no TIMP-1 has been detected in basal keratinocytes in chronic ulcers (Saarialho-Kere et
al, 1993b). Epidermal expression of collagenase-1 may be needed to facilitate keratinocyte
migration by degrading fibrillar collagens.
Not only is collagenase-1 involved in re-epithelialization, but it is abundantly expressed by various
types of stromal cells as well. Collagenase-1 mRNA is expressed in the granulation tissue of human
and porcine burn wounds (Stricklin et al, 1993; Stricklin et al, 1994b). Histologically defined, the
cells responsible for collagenase-1 expression may be macrophages, fibroblasts and endothelial
cells. Due to its ability to cleave fibrillar collagens, collagenase-1 undoubtedly participates in the
remodeling of the collagenous matrix. The regulation of collagenase-1 in the dermis is likely to
differ from that in the keratinocytes. E.g TGF-β upregulates collagenase-1 expression in cultured
keratinocytes, but downregulates its expression in fibroblasts (Mauviel et al, 1996). The
upregulation of fibroblast collagenase-1 may be induced by EGF or bFGF, as these growth factors
stimulate collagenase-1 expression at least in cultured quiescent human MRC-5 fibroblasts
(Edwards et al, 1987). According to an in vitro study with rabbit synovial fibroblasts, fibronectin
fragments bound to fibronectin receptor induce collagenase-1 expression (Werb et al, 1989). Thus,
degraded fibronectin in the wound bed may result in fibroblast collagenase expression. However,
granulation tissue fibroblasts are a cell population distinct from MRC-5/synovial fibroblasts, and
their responses to specific stimuli may vary from each other.
The gelatinases are differentially expressed and regulated during wound healing. Gelatinase A is
expressed by fibroblasts by both resting and healing human oral mucosa and skin (Oikarinen et al,
1993; Salo et al, 1994). No induction has been detected in the connective tissue cells of the wound
margin or the epithelium of wounded oral mucosa or skin (Saarialho-Kere et al, 1993b; Salo et al,
1994), unlike in porcine burn wounds, where gelatinase A mRNA is expressed mainly in the
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remodeling dermis adjacent to regenerating epidermis (Stricklin et al, 1994b). The activity of
gelatinase A during porcine skin wound healing remains rather stable, yet higher than in normal
skin, suggesting a role in prolonged remodeling of the matrix (Ågren, 1994). In human burn wound
fluid, gelatinase A appears at day 3-4 and the levels are low compared to gelatinase B (Young &
Grinnell, 1994). Cytokines such as TGF-β, bFGF, TNF-α or IFN-γ do not induce gelatinase A
expression in cultured wound fibroblasts (Salo et al, 1994).
Strong expression for gelatinase B mRNA is detected in basal and suprabasal keratinocytes in
nonwounded oral mucosa (Salo et al, 1994) which is in discrepancy with previous findings of the
absence of gelatinase B mRNA in normal skin (Pyke et al, 1992). Only the basal, migrating
keratinocytes express gelatinase B mRNA after oral mucosal incision, and cultured keratinocytes
enhance MMP-9 production after stimulation with TGF-β, TNF-α or IL-1β (Salo et al, 1994). In
regenerating human skin, gelatinase B mRNA is strongly expressed by basal keratinocytes in
suction blisters (Oikarinen et al, 1993), and may be regulated by extracellular factors via integrin
receptors (Larjava et al, 1993b). Gelatinase B mRNA expression is induced in the granulation tissue
as well (Salo et al, 1994). Analysis of gelatinase activity after burn injury and in skin wounds
reveals that gelatinase B is rapidly induced after injury, reaches maximum activity at 4-5 days after
injury, and gradually declines (Young & Grinnell, 1994; Ågren et al, 1994).
Thus, the gelatinases appear to have distinct roles during wound healing. Gelatinase A participates
in the long-term remodeling of the dermis, while gelatinase B is involved in reepithelialization.
Chronic wound fluids contain elevated levels of gelatinases, which indicates that excess of these
enzymes  may disturb wound healing (Wysocki et al, 1993; Bullen et al, 1995). High levels of
gelatinase B may, at least partly, originate from polymorphonuclear leukocytes of secondarily
infected chronic ulcers (Herrick et al, 1992; see Birkedal-Hansen et al, 1993; Brook & Frazier,
1998).
In vitro stromelysins-1 and -2 are able to degrade important components of the dermal matrix and
basement membranes, e.g. type IV collagen, elastin, laminin, and fibronectin (see Nagase, 1998).
The wide variety of substrates is reflected in the pattern of expression of stromelysin-1 in chronic
wounds. It is expressed by basal keratinocytes adjacent to but distinct from the migrating front, and
abundantly by stromal cells (Saarialho-Kere et al, 1994). Unlike stromelysin-1, stromelysin-2 is
expressed in chronic ulcers by the migrating front of keratinocytes and is not expressed by the cells
of the wound matrix (Saarialho-Kere et al, 1994). Not only are these two enzymes expressed by
distinct cell populations in chronic wounds, but also their regulation is indivudual. Keratinocytes in
the migrating front may be induced to express stromelysin-2 by EGF, TGF-α, or TNF-α, as these
cytokines induce stromelysin-2 in keratinocyte cultures, and are released in the wound area by
platelets and macrophages (Windsor et al, 1993; see Clark, 1995). However, these agents are unable
to induce stromelysin-1 in keratinocytes, which suggests a different stimulus for this enzyme
(Windsor et al, 1993). Thus, stromelysin-2 appears critical to keratinocyte migration, whereas
stromelysin-1 may be involved in the remodeling of the newly formed BM and of the wound matrix.
Furthermore, due to their ability to activate procollagenase (Suzuki et al, 1990), they may contribute
to collagenase-mediated proteolysis. Stromelysin-3 expression has been shown in late stages of
cutaneous wound healing in areas of inflammatory fibrosis (Wolf et al, 1992).
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5.7.  MATRIX METALLOPROTEINASES IN INTESTINAL DISEASE
MMPs in intestinal inflammation and wound healing are a rather uninvestigated area compared to
the vast amount of literature on repair processes of the skin. An immunohistochemical study by
Bailey et al (1994) was performed to investigate the role of collagenase-1, gelatinases A and B, and
stromelysin-1 in the intestinal connective tissue changes in Crohn`s disease and colitis ulcerosa. The
expression of collagenase-1 was observed in few isolated mononuclear cells, and that of gelatinase
A in occasional polymorphonuclear leukocytes, in both normal and IBD samples. In Crohn`s
disease, gelatinase B protein was expressed by polymorphonuclear leukocytes throughout the
intestinal wall. Stromelysin-1 protein was expressed by few mononuclear cells in normal tissue,
with a slight increase in diseased samples. According to this study, IBD associated changes in the
intestinal wall may partly result from MMP activity.
Most studies on MMPs in the intestine have focused on malignancies. Matrilysin expression, but
not stromelysin-1 or –2, has been shown in human gastric and colon carcinomas, suggesting that
inappropriate expression of matrilysin may contribute to the neoplastic phenotype (McDonnel et al,
1991). No expression of this enzyme was detected in normal tissue or other than carcinoma cells
(McDonnel et al, 1991). Another study provides evidence that matrilysin is expressed also by
premalignant cells of colon adenomas, but the levels of enzyme activity are lower than in
carcinomas (Yamamoto et al, 1994). Furthermore, truncated fibronectin induces matrilysin
expression in cultured WiDr cells (Yamamoto et al, 1994). No expression was detected in samples
of mildly inflamed regions of ulcerative colitis or normal intestine (Yamamoto et al, 1994). A role
for matrilysin in early events of tumorigenesis, and stromelysins-1 and –3 and gelatinase A in later
stages of tumor progression is suggested in a study by Newell et al (1994). According to them,
expression of matrilysin mRNA localizes mainly to adenoma/carcinoma cells, and of the other
MMPs to stromal cells of carcinoma tissue, while TIMP-1 mRNA is prominent in both carcinoma
and stromal cells. The relevance of matrilysin in intestinal tumors is further substantiated by the
suppression of intestinal tumorigenesis in mice lacking the metalloproteinase matrilysin (Wilson et
al, 1997). Gelatinase A and its inhibitor TIMP-2 mRNAs are expressed in colorectal adenomas and
carcinomas, mostly by peritumoral fibroblast-like cells (Poulsom et al, 1992). However gelatinase A
protein localizes mainly to neoplastic epithelial cells.
Not only MMPs, but also their activator uPA, are involved in intestinal neoplasias. According to
immunohistochemical studies, tumor infiltrates contain more uPA positive cells than normal tissues
(Kohga et al, 1985; Grøndahl-Hansen et al, 1991). UPA is produced by merely fibroblast-
like/endothelial cells of the stroma (Grøndahl-Hansen et al, 1991) or, according to another study,
also by tumor epithelial cells (Kohga et al, 1985).
5.8.  MATRIX METALLOPROTEINASES IN WOUND REPAIR IN OTHER TISSUES
Matrix metalloproteinases are involved in wound healing processes in tissues such as cornea and
respiratory epithelia. Matrilysin and gelatinases A and B mRNAs and proteins, and stromelysin-1,
TIMP-1 and TIMP–2 proteins are upregulated during rat corneal wound healing after an excimer
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laser keratectomy (Ye & Azar, 1998; Chung-Shien Lu et al, 1999). The overexpression of MMPs in
corneal wounds may delay wound healing, as has been shown in thermally injured rat and rabbit
corneas (Fini et al, 1996). In vitro studies on experimental wounds in human surface respiratory
epithelial cell cultures or bronchial mucosa organ culture have shown increased expression of
stromelysins-1 and –3 in migratory cells (Buisson et al, 1996). An upregulation of matrilysin after
injury to airway epithelium suggests a role for it in facilitating re-epithelialization (Dunsmore et al,
1998). The role of MMPs in alveolar epithelial wound repair is further substantiated by the finding
that exogenous collagenases enhance migration of mechanically injured alveolar epithelial cell
culture (Planus et al, 1999).
5.9.  MATRIX METALLOPROTEINASES AS TARGETS OF WOUND THERAPIES
Bacterial collagenase has been used for many years in debriding necrotic ulcers (Mekkes et al,
1997). This enzyme is under physiological conditions more effective in solubilizing both native and
denatured collagens than endogenous collagenases, thus severing the undenatured collagen fibers
holding the necrotic tissue within the wound bed (see Baharestani, 1999). A potent activator of
wound repair, glycyl-l-histidyl-l-lysine-Cu2+, enhances expression of the gelatinases as well as ECM
deposition (Siméon et al, 1999), which argues against the suggested harmful effect of excess MMPs
during wound healing. In the future, synthetic selective inhibitors of the MMPs may offer new
treatment options for those suffering from chronic ulcers. They are small peptide analogues of
fibrillar collagens, which interact with the zinc in the catalytic site of MMPs and  inhibit their
activity (see Kähäri & Saarialho-Kere, 1997; see Kähäri & Saarialho-Kere, 1999). Indeed, the
synthetic collagenase inhibitor GM6001, has been studied on murine wounds, and was found to
diminish the inflammatory response and angiogenesis, and to increase incisional wound strength
(Witte et al, 1998). However, caution is required when using broad spectrum MMP-inhibitors in
wound healing trials, since a growing number of studies indicate that certain MMPs serve beneficial
functions in wound repair. Also tetracyclines, retinoids and glucocorticoids may influence wound
healing through MMP-mediated cascades (see Kähäri & Saarialho-Kere, 1997; see Kähäri &
Saarialho-Kere, 1999).
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6.  AIMS OF THE STUDY
Matrix degradation and cell migration are intrinsic components of wound healing. Matrix
metalloproteinases comprise an important group of matrix-degrading enzymes, which are involved
in these processes during wound repair. Since it has been assumed, that excessive proteolysis may
delay wound healing, we planned to study the expression profiles of MMPs and their inhibitors in
normally healing and chronic wounds.
The specific aims of the study were as follows:
1.  To study the spatial and temporal expression patterns of various MMP:s (collagenases-1 and -3,
stromelysins-1 and -2, matrilysin and metalloelastase) in normally healing cutaneous wounds vs.
chronic ulcers.
2.  To define the expression of TIMPs-1, -2, -3 and -4 during cutaneous wound healing in vivo.
3.  To investigate the expression of MMPs (collagenases-1 and -3, stromelysins-1 and -2, matrilysin
and metalloelastase) and their inhibitors (TIMPs-1 and –3) in chronic intestinal erosions/ulcerations
caused by inflammatory bowel disease.
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7.  MATERIALS AND METHODS
7.1.  TISSUE SAMPLES
The study was approved by the Ethics Committee of the Department of Dermatology, Helsinki
University Central Hospital. All tissue samples were formalin-fixed and paraffin embedded.
Informed consent was obtained from individual subjects for all procedures.
Chronic dermal wounds.   Human skin samples (n=14) were collected from patients with chronic
leg ulcers undergoing excision and skin grafting prodecures at the Department of Plastic Surgery,
Helsinki University Central Hospital.  The patients were aged between 50 to 91 years.  The ulcers
were 3 months to 10 years old and had not responded to conservative treatment. Archival specimens
of chronic ulcers (n=6) / vasculitis (n=5) were obtained from the Department of Pathology, Helsinki
University Central Hospital.
Normally healing human wounds.   As controls for acute full thickness wounds (n = 25) biopsies of
normally healing donor areas on the anterior thigh were obtained from patients of the Department of
Dermatology, University of Helsinki, undergoing pinch grafting procedure (Ceilley et al, 1977). On
day 0, several pieces of skin measuring 8 mm in diameter and including a portion of the dermis
centrally, were excised from the donor area and transferred to the ulcer area. Biopsies containing the
donor area wound were taken 1, 2, 3, 4, 5, 6, 7 and 9 days postwounding from patients aged
between 55 to 94 years.
Suction blisters were obtained from Central Military Hospital, Helsinki. Blisters were induced on
the abdominal skin of four healthy volunteers under 30 years of age using a Dermavac device as
described previously (Kiistala & Mustakallio, 1968). Biopsies were taken 2, 4, and 9 days after
induction of the blister.
Normally healing experimental pig wounds.  3-cm long full-thickness incisional wounds were
made, using a surgical steel scalpel, on the skin of an anesthesized piglet. The wounds were closed
with Prolene sutures and, therefore, healed by primary intent. To ensure adequate sampling, three
wounds were excised at each time point: 1, 3, 5, 7, 10 and 14 days after wounding. The samples
were fixed in 10% formaldehyde, bisected in a plane perpendicular to the long axis of the wound,
and embedded in paraffin.
Chronic human gastrointestinal ulcers.  Specimens of duodenal ulcer (n=3), gastric ulcer (n=5),
ulcerative colitis (n=12), Crohn`s disease (ileum, n=7; colon, n=8), ischemic colitis (n=8),
histologically normal colon (n=3) and ileum (n=4) were obtained from the Department of
Pathology, University of Helsinki. All disease samples represented active, ulcerative phase of the
disease and were from adult patients.
Experimental model for intestinal anastomoses.  Animal studies were approved by the Regional
Committee for Ethics in Animal Research and Administrative Board at Helsinki University Central
Hospital. Adult male Wistar Rats (300g) were anesthesthetized with a single intramuscular injection
of ketamine (40mg/kg Vetalar®). The jejunum was cut at laparotomy with a steel scalpel
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approximately 10 cm from the Ligamentum of Treitz. Jejunal anastomoses were performed with one
layer of interrupted 6-0 polypropylene sutures (Prolene®, Ethicon, Norderstedt, Germany). After the
surgery the animals had free access to food and water. Animals were sacrificed at 1, 3, 4, 7, 9 and 14
days by an overdose of pentobarbital. To ensure adequate sampling, anastomoses were obtained
from two separate animals for each time point. Tissues were embedded in paraffin and cut at 5 µm.
7.2.  RNA PROBES
The production and specificity of the anti-sense human collagenase-1, stromelysin-1, stromelysin-2,
matrilysin, uPA, TIMP-1 and TIMP-3 (McDonnel et al, 1991; Busiek et al, 1992; Saarialho-Kere et
al, 1992; Sudbeck et al, 1992; Saarialho-Kere et al, 1994; Airola et al, 1995; Airola et al, 1998)
probes have been described. The MMP-13 cDNA plasmid MMP13HT3 (Johansson et al, 1997a)
was linearized within the multiple cloning site with HindIII and EcoR1 to allow transcription of
anti-sense (corresponding to nucleotides 1532-2042) and sense RNAs, respectively. The HME
cDNA used as a template was a kind gift from Steven Shapiro (Pulmonary Department, Washington
University, St Louis). The 650 bp fragment (600-1250) was generated by PCR using the primers
CAT ACG ATT TAG GTG ACA CTA TAC and TAA TAC GAC TCA CTA TA, resulting in a
product with SP 6  RNA polymerase recognition element at the 3´end and a T7 element at the 5´end.
Both antisense and sense probes were transcribed from this polymerase chain reaction product. The
specificity of the probes was confirmed by sequencing. The murine stromelysin-2 cDNA used as a
was kindly provided by Sabine Werner (Max-Planck-Institut für Biochemie, Martinsried, Germany)
(Madlener et al, 1996). As a control for nonspecific hybridization, sections in each experiment were
hybridized with 35S-labelled sense RNA from a bovine tropoelastin cDNA. The validity of this
probe as a negative control has been confirmed by Northern and by in situ hybridization assays
(Prosser et al, 1989; Saarialho-Kere et al, 1992; Saarialho-Kere et al, 1993b). In addition, negative
control probes transcribed from collagenases-1 and -3, stromelysins-1, matrilysin, HME, uPA as
well as TIMP-1 and -3 cDNAs in sense orientation were used.
Table 3. Probes and their sources
Probe (Study) Transcribed from bases/
 Genbank accession number
Source of the template
Collagenase-1 (I, II, III) 1-550 (550 bp)/ M13509 Dr Gregory Goldberg
Collagenase-3 (III, IV) 1532-2042 (511 bp)/NM_002427 Dr Carlos López-Otín
Stromelysin-1 (I, II, III) 1584-1801 (217 bp)/J03209 Dr Markku Kurkinen
Stromelysin-2 (II, IV) 1568-1743 (176 bp)/X07820 Dr Henning Birkedal-Hansen
Matrilysin (I, II) 14-813 (800 bp) /Z11887 Dr Lynn Matrisian
Macrophage metalloelastase (IV) 600-1250 (651 bp)/L23808 Dr Steven Shapiro
TIMP-1 (I, II, V) 1-313 (313 bp)/X03124 Dr David Carmichael
TIMP-3 (IV, V) 282-917 (636 bp)/U14394 Dr Veli-Matti Kähäri
UPA (II) 835-1661 (827 bp)/K03226 Dr Antti Vaheri
Stromelysin-2, murine (IV) 8-219 (212 bp)/X64020 Dr Sabine Werner
TIMP, tissue inhibitor of metalloproteinases; UPA, urokinase plasminogen activator
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The cDNA probes for stromelysin-2 and HME were amplified by polymerase chain reaction (PCR).
The template and primer concentrations were optimized for each probe. First, the reagents (primers,
template, nucleotides, reaction buffer, and the DNA polymerase) were mixed on ice. The PCR was
started with initial denaturing in 94°C for 2,5 minutes. This was followed by 35 cycles consisting of
1. 30 sec of denaturing (94°C) 2. 45 sec of annealing (55°C) and 3. 45 sec of elongation (72°C). The
PCR-product was purified by chloroform-isoamylalcohol extraction and ethanol precipitation. The
correct size of the PCR-product was checked by running it into an ethidium bromide-stained
agarose gel, and by visualizing it under UV-light.
7.3.  IN SITU HYBRIDIZATION
In situ hybridization was performed on 5-µm sections as described in detail (Prosser et al, 1989).
All samples were treated with proteinase K and were washed in 0.1 M triethanolamine buffer
containing 0.25% acetic anhydride. Sections were covered with 50 µl of hybridization buffer
containing 2.5-5 x 104  cpm/µl of 35S-labelled anti-sense or sense RNA probe. After hybridization at
50°C to 55°C for 18 hours in a humidified chamber, the slides were washed under stringent
conditions, including treatment with RNAse A to remove unhybridized probe. Following 10 to 45
days of autoradiography, the photographic emulsion was developed, and slides were stained with
hematoxylin and eosin. Samples previously positive for collagenase-1, stromelysin-1 and
stromelysin-2 (cutaneous wounds), for matrilysin (normal skin), for collagenase-3, macrophage
metalloelastase, TIMP-1 and -3 (breast and colon carcinomas) and for uPa (cutaneous wounds) were
used as positive controls in each experiment.
7.4.  IMMUNOHISTOCHEMISTRY
Immunohistochemistry was performed on sections serial to those used for in situ hybridization. The
peroxidase-antiperoxidase technique was applied using Vectastain Elite ABC kit (Vector
Laboratories, Inc., Burlingame, CA). After deparaffinazation and dehydration, the endogenous
proxidase activity was blocked with 0.3%-0.6% hydrogen peroxide. Non-specific staining was
blocked by treatment with normal serum. The monoclonal primary antibodies were incubated for
one hour at 37°C, and the polyclonal primary antibodies overnight at 4°C in a humidified chamber.
After incubation with the primary antibody (see Table 3 for the antibodies used), the secondary
biotinylated antibody was added, followed by avidin-biotin-peroxidase complex. Diaminobenzidine
or aminoethylcarbazole (Ki-67, CD3, CD31) were used as chromogenic substrates and Harris
hematoxylin as counterstain, as described in detail (Saarialho-Kere et al, 1993b). If necessary,
sections were pre-treated with 10 mg/ml trypsin, 1 mg/ml protease type XXVII (Sigma Chelmical
Co., St. Louis, MO), or antigen retrieval as described (von Boguslawski, 1994). Controls were
performed with mouse preimmune ascites fluid or with rabbit pre-immune serum.
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Combined immunohistochemistry and in situ hybridization was performed as described in detail
(Ranki et al, 1995). After RNAse-free immunohistochemical staining with CD68 antibody, the
samples were treated with 4% paraformaldehyde, washed with diethylpyrocarbonate-treated
phosphate-buffered saline, and hybridized for collagenase mRNA with 35S-labeled RNA as
described (Prosser et al, 1989). After autoradiography, the slides were developed and stained with
Mayer hematoxylin.
Table 4.  Antibodies and their sources.
Antibody Source Study
anti-gelatinase A IM33L, Calbiochem V
anti-stromelysin-1 prof. Howard Welgus, Washington University, USA II
anti-matrilysin prof. Howard Welgus, Washington University, USA I, IV
anti-TIMP-2 TIMP-2, Fuji Chemicals V
anti-TIMP-3 IM43L, Calbiochem, V
anti-TIMP-4 TIMP-4, Triple Point Biologics V
anti-CD3 A452, Dako IV
anti-CD20 U7021, Dako IV
anti-CD31 M823, Dako IV
anti-CD68 M814, Dako I, III, IV
anti-Ki-67 0505, Immunotech I, III. V
anti-type I procollagen MAB1912, Chemicon III, IV
anti-laminin-1 L-8217, Sigma Chemical Co I
anti-laminin-5 prof. Karl Tryggvason, Karolinska Institut, Stockholm, Sweden IV
anti-type IV collagen M785, Dako IV
anti-fibronectin A245, Dako I
anti-smooth muscle actin 6582, Bio-Makor IV
7.5.  CELL CULTURES
Normal human skin fibroblasts from a 26-year-old healthy volunteer were maintained in Dulbecco`s
modification of Eagle`s medium (DMEM, Flow Laboratories, Irvine, Scotland, UK), 2 mM
glutamine, 100 IU penicillin-G per ml, and 100 µl streptomycin per ml. Collagen gels were prepared
with bovine dermal collagen, Cellon (Strassen, France), containing 95% type I collagen and 5% type
III collagen. Eight volumes of Cellon were mixed with one volume of 10× concentrated DMEM and
1 volume of NaOH (0.05 M) in 0.2 M N-(2-hydroxyethyl)piperazine-N`-(2-ethanesulfonic acid) and
kept on ice. Cells were trypsinised, resuspended in DMEM supplemented with 10% fetal bovine
serum, mixed into a neutralized Cellon solution, and transferred into six-well plates. The plates
were incubated at 37°C for 1 h for collagen polymerization. After this, DMEM supplemented with
10% fetal bovine serum was added and the gels were detached from the sides of the wells. The gels
were incubated for 48 h before releasing the cells from the gels. As a control, fibroblasts were plated
as monolayer and cultured in DMEM supplemented with 10 % fetal bovine serum for 48 h.
Promonocytic U937 cells and CRL-1995 fibroblasts were cultured as previously described
(Wilhelm et al, 1997; Saarialho-Kere et al, 1993c). Human alveolar macrophages were isolated
from healthy adult smokers by saline bronchoalveolar lavage and cultured as described (Campbell et
al, 1991).
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7.6.  NORTHERN BLOT ANALYSIS
To isolate total RNA from the dermal fibroblasts inside collagen gels, the gels were briefly treated
with 0.5 mg collagenase (type II, Sigma) per ml in phosphate-buffered saline (pH 7.4) with  1 mM
CaCl2 . Total cellular RNA was isolated from all cell types studied by using the single-step method
(Chomczynski & Sacchi, 1987). Aliquots of total RNA (10-17 µg) were fractionated on 0.8%
agarose gel containing 2.2M formaldehyde, transferred to a Zeta-Probe filter (Bio-Rad, Richmond,
CA) by vacuum transfer (VacuGene XL; LKB, Bromma, Sweden), and immobilized by heating at
80°C for 30 min. The filter was prehybridized for 2 h and subsequently  hybridized for 20 h with 32P
labeled cDNAs (Thomas, 1980) for human collagenase-1 (Goldberg et al, 1986) and human
collagenase-3 (Johansson et al, 1997a). The  [32P]cDNA-mRNA hybrids were visualized with
autoradiography.
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8.  RESULTS
8.1. CUTANEOUS WOUNDS (II, III, V)
Table 5.  Typical patterns of MMP- and TIMP mRNA expression in normally healing cutaneous wounds and chronic
ulcers
Normally healing wounds Chronic ulcers
1-2 days old 3-5 days old 6-11 days old
MMPs e s e s e s e s
Collagenase-1 + + + + - + + +
Collagenase-3 - - - - - - - +
Stromelysin-1 + + + + - + + +
Stromelysin-2 - - + - - - + -
Matrilysin - -* - -* - -* - -*
Metalloelastase - - - - - - - +
TIMPs e s e s e s e s
TIMP-1 - + + + - + - +
TIMP-3 - + + + - + - +
*Matrilysin expression was detected in sweat glands in all types of cutaneous wounds.
MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinases; e, epidermal mRNA expression; s,
stromal mRNA expression
Collagenase-1 mRNA expression was detected in the basal and suprabasal keratinocytes bordering
the ulcer in both normally healing wounds, beginning the first postoperative day, and chronic
wounds. The signal was the strongest in the keratinocytes closest to the wound edge. In chronic
wounds, the number of positive keratinocytes was generally greater than in normally healing
wounds, in which the expression was shut off after completion of re-epithelialization. Cells of the
granulation tissue showed a strong expression for collagenase-1 mRNA in both normally healing
and chronic wounds. Histologically, the cells were either plump, macrophage/activated fibroblast-
like or spindle, fibroblast-like. Since it is difficult to define the cell type purely histologically,
immunostaining for procollagen-1, which is found inside of activated fibroblasts, was performed
(McDonald et al, 1986). According to this staining, many of the positive cells were activated
fibroblasts. (II,III)
Collagenase-3 mRNA was not expressed in the epithelium of any dermal wounds nor in the stroma
of normally healing wounds. An abundant expression of collagenase-3 was found in plump,
macrophage-like/activated fibroblast-like as well as spindle, fibroblast-like cells in the chronic
wound stroma of all samples investigated. The signal for collagenase-3 was generally located deeper
in the stroma than the signal for collagenase-1. The areas with collagenase-3 positive cells exhibited
either capillary proliferation or marked fibrosis. To define the cell type responsible for collagenase-
3 expression, immunohistochemical stainings for activated fibroblasts (procollagen-1),
macrophages (CD-68) (Pulford et al, 1989), and myofibroblasts (α-smooth muscle actin), which are
numerous in wound stroma, were performed. Colocalization of procollagen-I positivity and
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collagenase-3 mRNA showed that at least part of these cells were fibroblasts. Stainings for CD-68
and α-smooth muscle actin revealed that the positive cells were not macrophages nor
myofibroblasts. (III)
Stromelysin-1 mRNA was expressed in many of the chronic as well as re-epithelializing normally
healing wound samples, in basal keratinocytes a short distance from the migrating tip. In agreement
with the in situ data, immunohistochemical staining for stromelysin-1 protein was detected in basal
keratinocytes only in 2 days old normally healing wounds. (II)
Since stromelysin-1 can activate collagenase-3 by a two-step mechanism (Knäuper et al, 1996), a
subset of sections serial to those positive for collagenase-3 mRNA were hybridized with a cDNA
probe for this enzyme. Some chronic wound samples had stromal signal for stromelysin-1 (II,III),
but in areas that were negative for collagenase-3 mRNA (III). Like chronic ulcers, a subset of acute
wound samples had stromelysin-1 positive cells in the stroma. (II)
Stromelysin-2 mRNA was detected in 3- and 5-day-old normally healing wounds and in a majority of
chronic wound samples in the migrating front of the keratinocytes. No expression was detected in
samples with intact epidermis, nor in the stroma. (II)
Matrilysin mRNA was only detected occasionally in the ductal cells of the sweat glands, with no
epithelial or stromal expression in any wound samples investigated, which is in agreement with
previous findings on matrilysin in skin (Saarialho-Kere et al, 1995). (II)
Urokinase plasminogen activator is a potent activator of MMPs (see Birkedal-Hansen et al, 1993).
To assess whether it would be involved in the activation of MMPs expressed by the migrating
keratinocytes, its expression was studied in normally healing and chronic wounds. We found
expression for uPA mRNA in a majority of chronic ulcer samples in wound edge keratinocytes, and
in a similar location in normally healing wounds until day 5, when the expression was shut off after
re-epithelialization. Also, stromal signal for uPA mRNA was detected in many samples of both
normally healing and chronic wounds. (II)
TIMP-1 mRNA was never detected in the epidermis of chronic wounds, while in some normally
healing wound samples, the basal keratinocytes next to the migrating front showed signal for TIMP-
1 until re-epithelialization. Stromal signal for TIMP-1 was detected in almost all samples
investigated. In acute wounds, the signal was most prominent in the vicinity of blood vessels, while
chronic ulcers showed a more widespread pattern of distribution of stromal TIMP-1 mRNA. (II, V)
TIMP-2 protein was detected around the migrating epithelial tip as well as in the tissue below the
eschar in both normally healing wounds and suction blisters. In chronic wounds, TIMP-2 was
abundantly expressed by spindle, fibroblast-like stromal cells, but in only few samples in the
necrosis covering the epithelial tip. TIMP-2 protein was also found between the epithelial cells of
stratum granulosum and upper layers of stratum spinosum in all sample types. Secreted 72 kDa
gelatinase protein was found in great amounts near the epithelial edge, and in TIMP-2 positive
stromal areas in chronic ulcers. (V)
TIMP-3 mRNA was expressed in the epithelium of 3- to 5-day-old normally healing wounds. No
epithelial signal was found in suction blisters, chronic ulcers or vasculitis. Stromal signal for TIMP-
3 was found in all sample types in fibroblast-like cells and in occasional endothelial cells. The
signal was generally most intense in the chronic wounds, and during the first days in acute wounds,
locating mostly around the blood vessels. In normal skin, TIMP-3 mRNA was occasionally
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expressed by fibroblasts surrounding sweat glands. TIMP-3 protein located in the basal
keratinocytes near the wound edge in all wound types except suction blisters. As assessed by
staining for Ki-67 (Cattoretti et al, 1992), the positive cells were proliferating keratinocytes. All
wound types had TIMP-3 positive fibroblast-like cells and endothelial cells, while the staining was
most intense in chronic wounds. (V)
TIMP-4 protein was only produced by stromal cells near blood vessels in a few chronic wound
samples. All the samples of acute wounds remained negative. (V)
Samples of normal skin generally showed no signal for MMPs and TIMPs, except for matrilysin and
TIMP-3, as mentioned above. All of the samples hybridized with sense probes were negative, as
well as all of the immunohistochemical control samples performed with rabbit pre-immune serum
or mouse ascites fluid.
8.2.  INTESTINAL ULCERATIONS (I,IV)
Table 6.  Typical patterns of MMP- and TIMP- mRNA expression in ulcerative/erosive lesions caused by Crohn`s
disease or ulcerative colitis.
Crohn`s disease Colitis ulcerosa
MMPs e s e s
Collagenase-1 - + - +
Collagenase-3 - + - +
Stromelysin-1 - + - +
Stromelysin-2 + + + +
Matrilysin + - + -
Metalloelastase - + - +
TIMPs e s e s
TIMP-1 - + - +
TIMP-3 - + - +
MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinases; e, epidermal mRNA expression; s,
stromal mRNA expression
Collagenase-1 mRNA was detected in nearly all intestinal ulcers in the granulation tissue in large,
round cells in the bottom and the margins of the ulcer. Unlike in skin, no expression was found in
the epithelium bordering the ulcer. Double labeling  for collagenase-1 mRNA and CD-68 showed
that the positive cells were not macrophages and hence likely represented activated fibroblasts. The
signal was very intense in samples of IBD, while the samples of gastric and duodenal ulcers
displayed fewer positive cells. (I)
Collagenase-3 mRNA expression was detected in specimens of intestinal ulcers in the granulation
tissue beneath the ulcer bed. The positive cells were either plump, macrophage-like or spindle,
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fibroblast-like. As assessed by immunohistochemical staining for procollagen-1, at least part of
these cells were activated fibroblasts. No signal was found in the intestinal epithelium. (IV)
Stromelysin-1 mRNA was detected in granulation tissue beneath the ulcers in large, round cells in
areas corresponding to collagenase-1 mRNA expression. The expression of both enzymes was more
intense in deeper ulcers. The epithelium remained negative in all the samples. (I)
Stromelysin-2 mRNA was detected in almost all the samples of intestinal ulcers in the epithelium
bordering the ulcer or ruptured crypt abcesses. Immunolocalization of Ki-67 showed that the
positive cells were not of the proliferative phenotype. Staining of serial sections for laminin-5
demonstrated co-localization of this protein and stromelysin-2. Also matrilysin protein co-localized
with stromelysin-2 mRNA in the epithelial tip. Occasional lymphocyte- and macrophage-like cells
expressed stromelysin-2 in the inflamed lamina propria. Stainings for CD3 and CD20 demonstrated
that the majority of positive cells were not T- or B-lymphocytes, even though infiltrates of T-
lymphocytes were often found close to stromelysin-2 expressing cells. (IV)
Matrilysin mRNA as well as protein were expressed in almost all the ulcers in the epithelium
bordering the ulcer regardless of the ulcer type. Epithelial expression was also found associated with
cryptitis or crypt abcesses. Normal epithelium remained constantly negative for matrilysin mRNA
and protein. Immunohistochemical staining for Ki-67 demonstrated that matrilysin-positive cells
were not of the proliferative phenotype. Stainings for laminin-1 and fibronectin demonstrated that
the matrilysin-positive cells did not reside on a normal, intact BM. (I,IV)
Macrophage metalloelastase mRNA was abundantly expressed in all the ulcer samples investigated
by plump, macrophage-like cells of the inflammatory infiltrate and the wound. Particularly in
samples of ulcerative and ischemic colitis, prominent expression of HME mRNA was detected
beneath the shedding epithelium. The positive cells were proven to be macrophages by
immunohistochemical staining for CD68. Type IV collagen staining demonstrated continuity of the
basement membrane underneath the shedding epithelium. (IV) In the skin, only a few chronic ulcers
had HME mRNA positive, plump, macrophage-like cells in the vicinity of blood vessels (Vaalamo
et al, unpublished results).
TIMP-1 mRNA was detected in all investigated ulcer samples. Intense signal was located in the
granulation tissue at the base of the ulcer while no expression was found in the epithelium. (I)
TIMP-3 mRNA was abundantly expressed in intestinal ulcer samples. A great number of
macrophage- and fibroblast-like cells of the inflamed lamina propria and granulation tissue of the
ulcer bed expressed TIMP-3 mRNA. Also, cells around the blood vessel lumen were often positive
for TIMP-3 mRNA. At least part of these cells stained immunohistochemically with CD 31 and
were thus proven to be endothelial cells. An occasional signal for TIMP-3 mRNA was also detected
in samples of normal intestine around the blood vessels and in stromal cells. ( IV)
Samples of histologically normal intestine were generally negative for MMPs and TIMPs, except
for TIMP-3, as mentioned above. All of the samples hybridized with sense probes were negative, as
well as all of the immunohistochemical control samples performed with rabbit pre-immune serum
or mouse ascites fluid.
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8.3.  EXPERIMENTAL MURINE INTESTINAL ANASTOMOSES (IV)
Stromelysin-2 mRNA was expressed in the granulation tissue of rat ileal anastomoses from day 4 at
least until day 14.  Collagenase-3 was also expressed in the granulation tissue in plump,
macrophage-like cells in 3-, 4-, 7- and 14-day samples. No signal was found in the epithelium.
8.4.  EXPERIMENTAL PIGLET WOUNDS (II)
As in human wounds, collagenase-1, uPa and TIMP-1 mRNAs were expressed in basal
keratinocytes bordering the ulcer bed, and no expression was found when the re-epithelialization
was complete after day 5.
8.5.  HUMAN SKIN FIBROBLAST CULTURE (III)
Fibroblasts cultured on plastic as monolayer or fibroblasts stimulated with PMA, TGF-β or IL-1β
showed no signal for collagenase-3 mRNA after 48 hours. Culturing dermal fibroblasts inside a
collagen gel for 48 hours resulted in clearly detectable levels of  two collagenase-3 transcripts (2.0
and 2.5 kb). In the same cells, expression of collagenase-1 mRNA was detected in monolayer, and
the level of collagenase-1 mRNA was markedly enhanced when the cells were cultured inside a
collagen gel.
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9.  DISCUSSION
In this study, the expression patterns of matrix metalloproteinases of the collagenase and
stromelysin subgroups, and their specific inhibitors TIMPs, were investigated in human cutaneous
and intestinal wound samples using in situ hybridization and immunohistochemistry. In situ
hybridization is a relevant method for investigating the cellular origin of MMPs and their inhibitors,
since most MMPs are transcriptionally regulated i.e. the mRNA accumulates within the cell to
detectable levels following a certain stimulus, whereas the protein is often secreted from the cells
shortly after synthesis (Rodgers et al, 1994; Fini et al, 1996). However, these methods do not reveal
whether these enzymes are activated or not. Due to the general lack of immunohistochemical
antibodies detecting only the activated MMP form, in situ zymography on tissues or Westerns on
wound fluids or tissue would be the most suitable assays for that purpose.
9.1. COLLAGENASES-1 AND –3 AND STROMELYSINS-1 AND -2 IN CUTANEOUS
WOUND HEALING (II, III)
Figure 5. Collagenase-1, stromelysin-1 and -2, and TIMP-1 and -3 mRNA expression in a normally healing
human wound. BM, basement membrane. Modified from Pilcher et al, 1998.
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Our results on epithelial collagenase-1 expression, limited to basal keratinocytes bordering
normally healing wounds and chronic venous ulcers (II; III), are in agreement with the data in
rheumatoid, diabetic, and decubitus ulcers, in ulcerated pyogenic granulomas, and in normally
healing and burn wounds obtained by us and others (II; Saarialho-Kere et al, 1992; Saarialho-Kere
et al, 1993a; Saarialho-Kere et al, 1993b; Stricklin et al, 1993; Inoue et al, 1995). The expression of
collagenase-1 in wound edge epithelium is a constant finding, although the pathobiology of various
chronic ulcer types differs from each other. In normally healing wounds collagenase-1 is expressed
during the first postoperative day, and in in vitro wounds, as early as 4 hours after wounding (II; III;
Inoue et al, 1995). The same applies to cell culture conditions, where migrating keratinocytes in
contact with type I collagen express collagenase-1 at least after 24 hours of culturing (Pilcher et al,
1997). Shortly after complete re-epithelialization, no traces of collagenase-1 mRNA are found in
keratinocytes (II; Stricklin et al, 1993; Inoue et al, 1995). A similar pattern of expression
encountered also in healing rat and mouse skin wounds as well as in porcine burn- and incisional
wounds (II; Stricklin et al, 1994b; Okada et al, 1997; Madlener et al, 1998) suggests a major role for
this enzyme in dermal wound repair.
An interesting theory on the induction and role of collagenase-1 in keratinocyte migration has
recently been presented by Pilcher et al (1997). Contact of keratinocytes to interstitial collagen leads
to high affinity binding of integrin α2β1 to collagen. This induces expression of collagenase-1,
which degrades interstitial collagen into ¼ and ¾ fragments. These fragments denature in
physiological temperature to gelatin, losing the ability to bind to integrin α2β1 (Messent et al,
1998). The liberated keratinocyte is then able to extend and rebind to intact collagen further on the
wound bed. Once the contact with fibrillar collagen is abolished by completion of re-
epithelialization, collagenase-1 expression is shut off (II; III; Saarialho-Kere et al, 1993b; Stricklin
et al, 1993; Inoue et al, 1995). While altered cell-ECM contacts may result in the inhibition of
collagenase-1 expression, modulation of the intracellular calcium may provide for the signal to stop
collagenase-1 secretion in keratinocytes (Sudbeck et al, 1997).
Although in situ hybridization is not a quantitative technique, we can state that the number of both
epithelial and stromal collagenase-1 positive cells was higher in chronic than normally healing
wounds (II, III). Similarly, elevated collagenase-1 activity has been detected in chronic wounds
(Weckroth et al, 1996; Barone et al, 1998). Even though many human studies confirm the important
physiological role of collagenase-1 in  keratinocyte migration (Saarialho-Kere et al, 1993b; Stricklin
et al, 1993; Pilcher et al, 1997), transgenic mice expressing high levels of human collagenase-1 in
the epidermis suffer from delayed wound healing due to derangements in re-epithelialization (di
Colandrea et al, 1998). Also, the level of active collagenase-1 may vary; tissues and fluids from
normally healing wounds contain almost exclusively inactive forms of the enzyme, while fluids
from non-healing ulcers possess significant amounts of the active form of collagenase-1 (Nwomeh
et al, 1999). These results indicate that the homeostasis of active collagenase-1 is critical for
keratinocyte migration to succeed.
A member of the serine proteases, urokinase plasminogen activator (uPA), is expressed by
migrating keratinocytes in both normally healing and chronic wounds (II; Grøndahl-Hansen et al,
1988). The main task for plasminogen activation cascade during wound healing is probably fibrin
degradation, since wounds in plasminogen-deficient mice have impaired fibrin resolution and heal
poorly, while wounds in mice deficient in both plasminogen and fibrin heal as quickly as wounds in
normal mice (Bugge et al, 1996; Rømer et al, 1996). Most probably, plasmin also activates MMPs
such as collagenase-1 and stromelysin-2 in the wound edge (see Woessner, 1991). Although
members of both MMP- and serine protease families appear essential to keratinocyte migration, the
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migration proceeds, although slowly, with either plasminogen or MMP-activity excluded (Lund et
al, 1999). Keratinocyte locomotion is ceased only if mice lack both MMP activity and plasminogen
(Lund et al, 1999). These findings suggest that MMPs and serine proteases can perform each others`
tasks during wound repair.
Collagenase-1 expression is not limited to the epithelium. Stromal fibroblast-like as well as
macrophage-like cells express collagenase-1 in all types of wounds examined (II; III; Saarialho-Kere
et al, 1992; Saarialho-Kere et al, 1993b; Stricklin et al, 1993). It is tempting to speculate that
moderate expression of collagenase-1 in normally healing wounds is a part of the normal, reparative
process. The prolonged presence of high amounts of collagenase-1 in chronic dermal wounds, and
even in conditions preceding chronic ulcers, may implicate excess proteolysis leading to disturbed
healing of the lesions (II; III; Weckroth et al, 1996; Herouy et al, 1998). A recent study by Nwomeh
et al (1999) suggests that at least in chronic venous ulcer fluids, neutrophil collagenase is the
predominant collagenase. We have not assessed the expression of this enzyme in wounds, but its
origin most likely are the polymorphonuclear leukocytes, which are more or less abundant in
chronic wounds (Herrick et al, 1992). During the inflammatory phase of acute wound healing, the
neutrophils are the first cells to arrive to the injured area (see Clark, 1995), which makes it probable
that collagenase-2 liberated from their granules would be responsible for initiating collagenolysis in
wounds. This neutrophilic reaction may persist too long in chronic wounds, and together with the
lack of activated macrophages (Moore et al, 1997), may lead to altered cytokine profiles and
excessive MMP expression.
The third MMP capable of degrading fibrillar collagens, collagenase-3 (Freije et al, 1994; Knäuper
et al, 1996), has a different pattern of expression in wounds than collagenase-1. Its expression was
never detected in the epithelium of any wound type, nor in the stroma of normally healing wounds
(III). Contrasting acute dermal wounds, stromal fibroblasts are able to express MMP-13, when acute
oral wounds heal (Ravanti et al, 1999b). This may reflect the different cellular environments of
dermal and mucosal fibroblasts, and imply that studies on mucosal healing cannot always be directly
extrapolated to dermal wound healing. Interestingly, collagenase-3 mRNA is expressed by inflamed
gingival keratinocytes protruding towards underlying connective tissue. These MMP-13 positive
cells colocalize with laminin-5 (Uitto et al, 1998), and are detected in a localization similar to
gelatinase A in inflamed oral mucosa (Mäkelä et al, 1999). Thus, gelatinase A and collagenase-3
may be operational in oral wound healing and in pathological epithelial migration, while
collagenase-1 assists in keratinocyte migration during dermal wound repair (Mäkelä et al, 1999).
This is supported by our findings on collagenase-3 in invasive carcinomas of the skin and the
mucosa, but not in the epithelium of healing cutaneous wounds (III; Airola et al, 1997; Johansson et
al, 1997c; Johansson et al, 1999).
In the skin, collagenase-3 mRNA expression was detected only in fibroblast- and macrophage-like
cells in fibrotic areas of chronic venous ulcers deeper in the wound bed than collagenase-1 mRNA,
suggesting distinct roles for these enzymes (III). At least part of the collagenase-3 positive cells
were fibroblasts, as assessed by staining for procollagen-1 (III). These fibroblasts may be stimulated
to express collagenase-3 by contact with surrounding collagenous matrix mediated by integrin
receptors α1β1 and α2β1, based on the following findings: 1) normal human skin fibroblasts
cultured inside a three-dimensional collagen-gel, but not when grown in monolayer, express
collagenase-3 (III) and 2) the induction generated by three-dimensional collagen is mediated by
integrin receptors α1β1 and α2β1 (Ravanti et al, 1999a). Since collagenase-3 has a wider variety of
substrates than collagenase-1, being also able to degrade e.g. gelatin (Knäuper et al, 1996), it may
participate in the remodeling of the immature collagenous matrix by degrading fibrillar collagens
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and their cleavage products, as well as other connective tissue components. Furthermore,
collagenase-3 activates progelatinase B in a two-step cleavage mechanism in vitro (Wysocki et al,
1993; Bullen et al, 1995; Knäuper et al, 1997), and may activate this enzyme also in chronic ulcers
in vivo. MT1-MMP activates both collagenase-3 and gelatinase B, yet by distinct mechanisms (see
Murphy et al, 1999). MT1-MMP, gelatinase B and collagenase-3 are expressed concomitantly at
least in rat wounds (Okada et al, 1997), and vulvar squamous cell carcinomas (Johansson et al,
1999), and all these enzymes can be involved in complex activation cascades of the wound
environment.
In our dermal wound samples, stromelysin-1 was expressed by keratinocytes distinct from but
adjacent to the migrating front of keratinocytes, in part of both normally healing and chronic
wounds (II). Due to its location stromelysin-1 is not likely to participate in keratinocyte migration.
Rather, it may participate in the remodeling of the newly formed basement membrane. Stromelysin-
1 is expressed in proliferating keratinocytes that already have a BM beneath them, composed of the
stromelysin-1 substrates laminin and type IV collagen (II; Juhasz et al, 1993; Wilhelm et al, 1987).
Also tenascin, a glycoprotein abundant in healing wounds, is readily degraded by stromelysin (see
Imper & van Wart, 1998). During wound healing, tenascin mRNA is expressed by basal
keratinocytes, resulting in an intense staining of this glycoprotein in the papillary dermis underneath
the incomplete BM, as assessed by staining of heparan sulphate and laminin (Aukhil et al, 1995;
Latjinhouwers et al, 1996; Vaalamo et al, unpublished results). Stromelysin-1 may also act in
removing excess tenascin after completion of migration, when its cell-spreading activities are no
longer needed. The activity of stromelysin-1 may be controlled by TIMP-1 and –3 which in acute
wounds are expressed in areas partly colocalizing with stromelysin-1 expression (II; V).
As shown in this study for the first time, stromelysin-2 mRNA is expressed in migrating
keratinocytes in both acute and chronic skin wounds, as well as in full-thickness murine wounds (II;
Madlener et al, 1996). Wounding of the skin results in transition of stationary keratinocytes into
migrating cells, and these cells start to actively produce laminin-5 (Larjava et al, 1993a; Pyke et al,
1994). Production of this protein partly co-localizes with stromelysin-2 expression (II; Vaalamo,
unpublished results; Larjava et al, 1993a). Laminin-5 has been shown either to stimulate (Zhang &
Kramer, 1996), or to inhibit epithelial cell movement (O´Toole et al, 1997). Furthermore, specific
cleaveage of laminin-5 by gelatinase A induces migration of breast epithelial cells (Giannelli et al,
1997). In dermal wounds, the expression and activity of gelatinase A is rather weak (Salo et al,
1994; Young & Grinnell, 1994). Since wide-spectrum proteinase stromelysin-2 is expressed in
approximity or co-inciding with laminin-5 production, it is tempting to speculate that it participates
in degradation of this BM component in healing wounds, and possibly accelerates re-
epithelialization. However, the capacity of stromelysin-2 to degrade laminin-5 remains
uninvestigated to our knowledge, and needs to be determined. Fibronectin, which is abundant in the
granulation tissue, provides another candidate target for stromelysin-2 (Clark et al, 1992; Juhasz et
al, 1993). However, recent studies suggest that at least in chronic wounds, neutrophil elastase is the
proteinase responsible for excessive degradation of fibronectin (Rao et al 1995; Grinnell & Zhu,
1996), and may perform this task in normally healing wounds as well.
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9.2. TISSUE INHIBITORS OF METALLOPROTEINASES-1, -2, -3 AND -4 IN
CUTANEOUS WOUND REPAIR (II,V)
In this study, we found TIMP-1 and TIMP-3 mRNA expression only in the epithelium of normally
healing wounds (II; V). Contrasting this, TIMP-3 protein was widely expressed by proliferating
keratinocytes in both wound types. This discrepancy may be explained by mRNA levels that are too
low in chronic wounds to be detected by in situ hybridization. TIMP-1 and –3 are regulated in
response to cell-ECM interactions and by various cytokines; e.g. laminin-1 inhibits TIMP-1
expression while collagen type I stimulates it in cultured keratinocytes (Petersen et al, 1990).
Furthermore, TGF-β stimulates the expression of TIMP-3 at least in primary human keratinocytes
(Airola et al, 1998). TIMP-1 and –3 expression induced in wound edge keratinocytes may be needed
in 1) the protection of the newly formed basement membrane from degradation by epithelial MMPs,
e.g. stromelysin-1 (II), 2) in the regulation of keratinocyte proliferation due to their growth
promoting activities (see Gomez et al, 1997), or 3) the protein released from the cells into the matrix
may be needed to inactivate excess MMPs produced by the leading edge of keratinocytes. TIMP-2
protein locates beneath the migrating front of keratinocytes, and it is found in greater amounts in
acute wounds than in chronic ones (V). Whereas TIMPs-1 and –3 may act chiefly in neutralizing
secreted collagenase-1, TIMP-2 may neutralize the gelatinases, according to their in vitro
preferences (Howard et al, 1991; Apte et al, 1995).
Expression of TIMPs is not limited to epithelial structures. In addition to TIMP-2 protein,
expression for TIMP-1 mRNA, and TIMP-3 mRNA and protein was detected in the stromal
compartment of healing wounds. Stromal expression of these enzymes may be needed in the
inactivation of stromal MMPs such as collagenase-1 and stromelysin-1 (II; III; Stricklin et al, 1993),
and collagenase-3 in chronic ulcers (III). Localization of TIMPs-1 and –3 surrounding blood vessels
suggests a role in regulating wound angiogenesis (Johnson et al, 1994; Anand-Apte et al, 1997).
TIMP-4 is the most recently cloned of the TIMPs (Greene et al, 1996). It exhibits a restricted pattern
of moderate expression in human tissues such as the heart, kidney, placenta, colon and testes
(Greene et al, 1996). Accordingly, we found TIMP-4 protein only in sporadic activated fibroblast-
like cells of chronic wound stroma. Thus, the role of TIMP-4 appears a minor one in dermal
wounds, compared to other TIMPs (II; V).
Tissue inhibitors of metalloproteinases are considered to be the major inhibitors for MMPs.
However, unspecific inhibitors such as alpha 2-macroglobulin may also participate in the regulation
of MMPs in wound environment, since collagenase-1-alpha 2-macroglobulin complexes have been
detected in both normally healing burn wounds and chronic venous ulcers (Grinnell et al, 1998).
Our studies indicate that the relative lack of local inhibitors of MMPs, TIMPs-1, -2, and –3, in
chronic ulcers may lead to inadequate activation of MMPs, with subsequent digestion of the ECM,
and perhaps, delayed migration and disturbed wound healing.
Excluding the suction blisters, the wound samples we used in our studies were from elderly people
(II; III; V). Aging alters the inflammatory response to injury; wounds of the aged show an early
marked increase in the neutrophil response, and delayed monocyte/macrophage and lymphocyte
appearance together with alterations in the inflammatory and endothelial cell adhesion molecule
profiles (Ashcroft et al, 1998). The age-related increase in gelatinases A and B with gelatin
degradation and proteinase activity is detected in acute wounds, while collagenase-1 and
stromelysin-1 profiles do not differ in the young and the aged (Ashcroft et al, 1997a). TIMP-1 and -
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2 mRNA levels in wounds of the young are elevated between 3-21 days, while the aged have a
constant basal level expression of TIMP-1 and –2 (Ashcroft et al, 1997b). Our results on MMP-
expression in normally healing wounds represent the events in wounds of the aged, and may differ
in some aspects from normally healing wounds in the young. However, the fact that both the acute
and the chronic wound samples examined were from people over 50 years of age, makes comparing
of these wound types more reliable.
9.3. COLLAGENASES-1 AND –3, STROMELYSINS-1 AND –2, MATRILYSIN
AND MACROPHAGE METALLOELASTASE
 IN INFLAMMATORY BOWEL DISEASES (I, IV)
Figure 6. Collagenases-1 and -3, stromelysins-1 and -2, matrilysin, macrophage metalloelastase, and TIMPs-1 and -3
mRNA expression in IBD with intestinal ulceration.
Contrasting the only previous study demonstrating sporadic collagenase-1 protein expression in IBD
(Bailey et al, 1994), we detected abundant expression of collagenase-1 mRNA in the stroma of IBD
lesions (I). The signal located beneath the ulcers in plump cells, which were most probably activated
fibroblasts, since double labeling showed distinct location of collagenase-1 mRNA and the
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macrophage marker CD-68 (I). Not only was collagenase-1 mRNA expressed in IBD; a majority of
chronic intestinal ulcer samples showed expression for collagenase-3 mRNA in the granulation
tissue, yet in fewer cells than collagenase-1 (I; IV). Unlike in skin, the signal was not confined to
fibrotic areas or cells surrounding blood vessels. Rather, deeply penetrating ulcers showed diffuse
signal in fibroblast and macrophage-like cells of the granulation tissue (IV). In both dermal and
intestinal ulcers, at least part of the positive cells were shown to be fibroblasts, while we could not
demonstrate any macrophage being responsible for the expression of collagenase-3 mRNA (III; IV).
The epithelium remained negative for both collagenase-1 and collagenase-3 in the gut (I; IV).
Inflammation in the intestine may be responsible for the induction of MMPs in IBD. Chronic
immune activation outside as well as inside the lamina propria has been suggested in these diseases
(Pallone et al, 1987). Strong evidence for T-cell mediated damage of the intestine is obtained from
studies with fetal ileal organ explants (Pender et al, 1996; Pender et al, 1997); collagenase-1,
gelatinase A, and stromelysin-1 are produced in response to T-cell activation, and they are
upregulated in the mesenchymal cells by IL-1β and TNF-α. Elevated levels of IL-1β and TNF-α
have been shown in IBD in vivo as well (Ligumsky et al, 1990; Cappello et al, 1992; Murch et
al,1993). Furthermore, recombinant stromelysin-1 added to mucosal explants results in tissue
destruction within 24 hours, while synthetic inhibitor of MMPs reduces mucosal damage caused by
T-cell activation (Pender et al, 1997). This provides evidence that activation of lamina propria T-
cells responding to luminal antigens may lead to tissue damage by MMPs. T-cells may not only
mediate tissue damage by altered cytokine/growth factor profiles, but are also able to express MMPs
such as stromelysin-2 and gelatinase B (Conca & Wilmroth, 1994; Johnatty et al, 1997). In our
studies, IBD specimens showed intense mRNA expression for collagenase-1, stromelysin-1, and
HME, and moderate expression for collagenase-3 by the stromal cells (I; IV). While the
collagenases may be responsible for the digestion of fibrillar collagens, stromelysin-1 and HME
could mediate the loss of lamina propria glycosaminoclycans such as chondroitin and dermatan
sulphates (Murch et al, 1993; Pender et al, 1996; see Chandler et al, 1997; see Wilson 1998).
Altogether, these results indicate that T-cells may have an important role in mediating tissue
damage by MMPs in IBD in vivo, too. Mast cells, which are particularly numerous in the intestinal
wall (see Pope, 1998), release serine proteinases chymase and tryptase and may contribute to the
intestinal damage by activating stromal MMPs collagenase-1 and stromelysin-1 (Lees et al, 1994).
As in dermal wounds, stromelysin-2 mRNA was detected in migrating intestinal epithelium
bordering the ulcers, erosions and ruptured crypt abscesses, partly co-localizing with laminin-5 (I;
IV). KGF is a cytokine capable of inducing stromelysin-2 at least in cultured HaCat keratinocytes,
and its mRNA and protein expression is upregulated in both murine dermal wounds and, up to 150-
fold, in IBD (Werner et al, 1992; Brauchle et al, 1996). This potent mitogen for both keratinocytes
and gastrointestinal epithelial cells may contribute to stromelysin-2 induction in both dermal and
intestinal wounds in humans. In IBD, we detected stromelysin-2 in areas of disrupted epithelium
(IV), and analogously, expression of KGF was particularly high in areas characterized by epithelial
damage in IBD (Brauchle et al, 1996).
Like collagenase-1 in dermal wounds, matrilysin was detected in migrating intestinal epithelial cells
(I; IV). Both matrilysin mRNA and protein were expressed by the wound edge intestinal epithelium,
while in the skin, only normal glandular epithelium expresses matrilysin, with no induction during
wound healing (II; Saarialho-Kere et al, 1995). This may reflect differences in the composition of
the ECM in these organs. While dermis is dense and rich in fibrillar collagens, the lamina propria of
the intestine is loose and cellular, and there is no such need for degradation of fibrillar collagen as in
the skin. Our results also support the previous findings of matrilysin mainly in cells and tissues of
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secretory epithelial origin (see Wilson et al, 1998). In contrast to findings in mice (Wilson et al,
1995), matrilysin is not expressed in intact intestinal mucosa (I; IV). In mice, matrilysin co-localizes
in the Paneth cell granules with bactericidal cryptidins, and in vitro it is able to process cryptidin
precursors (Wilson et al, 1999). Thus, it may function in intestinal mucosal defense in mice. We did
not assess matrilysin in normally healing intestinal wounds due to the lack of proper samples. This
makes it difficult to judge whether matrilysin really is needed for normal wound repair, without
underlying disease and inflammation. Matrilysin may also play a role in the pathogenesis of
inflammatory bowel disease, since it is able to process proTNF-α, an inflammatory mediator found
in IBD tissues (Cappello et al, 1992; Murch  et al, 1993; Chandler et al, 1996).
Our study provides the first evidence of matrilysin in human intestinal epithelium without malignant
progression (I). Earlier studies focused on the role of matrilysin in both premalignant adenomas as
well as colon and gastric carcinomas, with no expression in normal or inflamed intestine
(McDonnel et al, 1991; Newell et al, 1994; Yamamoto et al, 1994). It has been suggested, that
gastric carcinomas use integrin α6β4, laminin-5, and laminin-1 as the machinery of adhesion and
invasion (Tani et al, 1996). Among these, β4-integrin subunit is degraded by matrilysin in vitro (von
Bredow et al, 1997). The anchoring complex components α6 and β4 integrin subunits are a part of
normal intestinal epithelium as well (Leivo et al, 1996). Since expression of matrilysin by migrating
cells of the intestinal epithelium was a constant finding (I; IV), it is tempting to speculate that both
benign and malignant intestinal epithelial cells use matrilysin to detach from the anchoring complex
by degrading β4-integrin subunit, when migrating.
EGF is involved in protection as well as healing of gastrointestinal mucosa (Konturek et al, 1991). It
may, together with TGF-α, stimulate cell proliferation and DNA synthesis in the healing of gastric
lesions, and protect the intestine against ethanol or stress induced damage in rats (Konturek et al,
1992). Other cytokines that have been shown to accelerate healing of GI-lesions include PDGF and
TGF-β (Mustoe et al, 1990; see Jones et al, 1999). Culturing enterocytes on collagen stimulates
migration more than laminin or fibronectin (Basson et al, 1992a; Basson et al, 1992b). However,
EGF and TGF-β stimulate cultured enterocytes migration only on laminin (Basson et al, 1992a;
Basson et al, 1992b). Different effects on migration may reflect specific repair processes of the
intestine; namely restitution and repair by reepithelialization and proliferation. These growth factors
may also influence the expression of matrilysin and stromelysin-2 in the migrating cells. It would be
interesting to know whether these enzymes are involved in both repair processes. Unfortunately, we
were not able to determine any areas with only restitution going on. Therefore we can only suggest
that in the intestine, cells migrating over the connective tissue express matrilysin and stromelysin-2,
and require these enzymes probably for degradation of ECM/BM components (I; IV).
No expression of matrilysin was detected in the connective tissue compartments of dermal or
intestinal ulcers (I; II). However, macrophage metalloelastase was expressed intensively by
macrophage-like cells in IBD (IV). All the samples of IBD were positive for metalloelastase, and
the positive cells located in two distinct areas: 1) underneath the shedding epithelium and 2) within
the macrophage-rich zone of the inflamed connective tissue. HME has a broad substrate specificity
with the ability to degrade BM components such as type IV collagen, laminin and fibronectin (see
Chandler et al, 1997). We suggest a role for this macrophage-derived enzyme in the shedding of
intestinal epithelium, possibly preceding formation of erosion/ulcer during the course of IBD (IV).
Deeper in the stroma, this enzyme may also aid in macrophage migration, a process in which it has
previously been implicated (Shipley et al, 1996).
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9.4. TISSUE INHIBITORS OF METALLOPROTEINASES-1 AND –3  IN
INFLAMMATORY BOWEL DISEASE (I,V)
Like in chronic cutaneous wounds (II; V), no TIMP-1 nor TIMP-3 mRNAs were detected in the
epithelium of chronic intestinal ulcers (I; IV). No TIMP transcripts were detected in the epithelium
even in intestinal samples with histologically active re-epithelialization (IV). When comparing the
expression of TIMP-3 in cutaneous and intestinal wounds, one must bear in mind its tightly
scheduled expression; only 3-5 days old skin wounds exhibited epithelial transcripts for TIMPs (I;
V). Determining the duration of intestinal ulcers and erosions is practically impossible, and clinical
course of the IBD suggests rather long-lasting injuries.
The inflammatory infiltrate of the chronic intestinal ulcers and erosions showed strong signal for
both TIMP-1 and TIMP-3 (I; IV). The expression of these inhibitors co-localized partly with that of
MMPs such as collagenases-1 and –3 and stromelysin-1 (I; IV).  TIMPs may be upregulated in the
intestine to prevent damage caused by the MMPs. Various cytokines and growth factors of the
inflamed intestine may trigger TIMP production, and it is tempting to speculate that factors
beneficial to intestinal wound healing, such as IL-10 and EGF (see Anand-Apte et al, 1996; Pender
et al, 1998a; see Jones et al, 1999) would mediate the upregulation of TIMPs, and in this way limit
tissue destruction by MMPs.
On one hand, the location of TIMP-3 mRNA around blood vessels in IBD proposes a role for it in
stabilizing vessel walls, since it has antiangiogenic properties (Anand-Apte et al, 1997). On the
other hand, overexpression of TIMP-3 in rat vascular smooth muscle cells promotes apoptosis
(Baker et al, 1998) which does not exclude an alternate role for TIMP-3 in mediating apoptosis of
vascular cells with subsequent vessel regression.
Inflammatory bowel disease lesions have elevated levels of TNF-α (Murch et al, 1993; Ligumsky et
al, 1990), which may mediate tissue damage by accelerating the inflammatory response. The p55
TNF receptor immunoadhesin prevents TNF-α-mediated MMP-production and tissue damage of the
intestine (Pender et al, 1998b). Conversion of this cytokine from proform into active form can be
prevented by TIMP-3, an inhibitor of TACE (TNF-α converting enzyme) (Amour et al, 1998).
Thus, TIMP-3 may inhibit proteolysis not only by local inhibitory acitivity, but also by preventing
MMP-production.
9.5. MATRIX METALLOPROTEINASES IN ANIMAL MODELS
Even though MMPs have been implicated in developmental and disease processes, their actual role
remains unraveled. Many in vitro studies have elucidated their substrate specificities and activities,
but none of these results have been proven in vivo (see Woessner, 1998). Therefore, it can only be
suggested that they degrade ECM molecules also in vivo. To resolve the actual consequences of
MMP activity in tissues, various MMP-knockout mice have been generated (see Shapiro, 1998).
Indeed, different in vivo tasks for MMPs can be suggested according to these studies. For example,
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macrophages from HME-deficient mice fail to penetrate basement membranes (Shipley et al, 1996),
and gelatinase A and matrilysin deficiencies inhibit tumor growth (Itoh et al, 1998; Wilson et al,
1997), indicating roles for these MMPs in macrophage migration and tumor cell invasion,
respectively. However, wound healing has only been investigated in mice deficient in stromelysin-1
(Bullard et al, 1999). These mice display no disorders in migration or reepithelialization, but suffer
from impaired wound contraction (Bullard et al, 1999). The viability and rather normal development
of many MMP-knockout mice suggest that many of the tasks of a single enzyme can be performed
by other proteinases, due to overlapping degradative activities. This functional overlap is
demonstrated by impaired wound healing in mice with either plasminogen deficiency or galardin-
blocked MMP-activity, but a total failure to heal in mice with both plasminogen deficiency and
galardin-treatment (Lund et al, 1999).
Many of the studies cited here were performed with mice, rats, rabbits or pigs (Stricklin et al,
1994b; Fini et al, 1996; Madlener et al, 1996; Okada et al, 1997; Madlener et al, 1998). We too
performed part of our work with animals: collagenase-1 and TIMP-1 mRNA expression in
incisional pig wounds confirmed the findings in humans (II), as was the case in burn wounds of pigs
and humans (Stricklin et al, 1993; Stricklin et al, 1994b). In normally healing rat wounds, MMPs
such as collagenase-3, gelatinase A, MT1-MMP and stromelysin-1 were coordinately expressed,
and MT1-MMP was shown to activate progelatinase A in the wound stroma (Okada et al, 1997).
These results partly correspond to those of humans. Of interest was the expression of collagenase-3
in the migrating epithelium, which did not occur in normally healing human skin wounds (Okada et
al, 1997; III). This may be explained by rat collagenase-3 considered as the counterpart of human
collagenase-1 (Knäuper et al, 1996). Similarly as in humans, no matrilysin was found during rat skin
wound healing (Okada et al, 1997). Expression of stromelysin-2 in wound healing in mice, and lack
of the enzyme in rat wounds, as well as different MMP-expression patterns in rat and rabbit corneal
wound healing, provide examples of MMP variations between rodents (Madlener et al, 1996; Fini et
al, 1996; Okada et al, 1997). In order to determine stromelysin-2 and collagenase-3 expression in
normally healing intestinal wounds, we used samples of rat ileal anastomosis (IV). These samples
provided somewhat unexpected results: stromelysin-2 mRNA expression did not localize in the
migrating epithelium, but in the granulation tissue, as the expression for collagenase-3 mRNA (IV).
In mice, matrilysin was constitutively expressed by Paneth cells in crypts of normal small intestine
(Wilson et al, 1995), which was not supported by our work in human intestine (I; IV). Rats with
acetic acid induced gastric ulcers displayed a rapid elevation in collagenase-1 and gelatinase B
levels, with gradual return to control values during the healing phase (Baragi et al, 1997). Colonic
anastomoses resulted in elevated MMP and TIMP-1 expression confined to the suture line, while
anastomoses combined with ischemia or colonic obstruction resulted in a more widespread
expression of MMPs and TIMP-1 (Savage et al, 1997; Savage et al, 1998). Data on MMPs in acute
human intestinal lesions would be valuable, but such samples are difficult to obtain. Altogether,
these slightly varying, species dependent results indicate that even though work that has been done
with animal models provides valuable information, direct conclusions to healing human wounds
cannot be drawn.
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10. CONCLUSIONS
Wound healing is an orderly process, during which the disrupted epithelium is restored by cell
migration and proliferation, and the injured tissue is replaced by the newly deposited matrix. Most,
if not all the components of the extracellular matrix and the basement membranes can be degraded
by matrix metalloproteinases (MMPs). The expression of MMPs is controlled by cytokines, growth
factors, oncogenes, and changes in the cell-cell and cell-matrix interactions. Tissue inhibitors of
metalloproteinases (TIMPs) -1, -2, -3 and -4, are the most important inhibitors of MMPs, whose
activities are required not only to prevent excessive proteolysis of tissues but also to regulate e.g.
cell proliferation and angiogenesis. MMPs have been implicated in various physiological and
pathological conditions that require remodeling of the extracellular matrix. In dermal wounds, they
may serve a role in e.g removing the devitalized tissue, in dissecting the way for migratory cells, or
in activating latent growth factors.
Based on our results, migrating keratinocytes express MMPs, collagenase-1 and stromelysin-2,
during wound healing. Expression of collagenase-1 is induced rapidly after injury, possibly by the
keratinocyte contact to extracellular matrix. Urokinase plasminogen activator, which is expressed by
the migrating keratinocytes as well, may lead to plasminogen activation cascade and degradation of
the fibronectin and fibrin-rich provisional matrix, together with activation of collagenase-1 and
stromelysin-2. Collagenase-1 and stromelysin-1 participate also in the remodeling of the newly
deposited connective tissue. Matrilysin is not involved in dermal wound healing.
TIMPs-1 and -3 are expressed by basal keratinocytes further from the migrating front than
collagenase-1, where they may act in protecting the re-established basement membrane from
degradation. TIMP-1, TIMP-2 and TIMP-3 are expressed also in the matrix, probably neutralizing
the MMPs secreted by the epithelial as well as the stromal cells. TIMP-4 appears to play a minor
role in human wound healing.
The patterns of MMPs and their inhibitors are qualitatively rather similar in acute and chronic
wounds. The major differences include 1) higher quantities of e.g. collagenase-1 mRNA positive
epithelial and stromal cells in chronic wounds 2) presence of collagenase-3 mRNA in the stroma of
chronic, but not in acute wounds and 3) lack of TIMP-1 and TIMP-3 mRNA expression in
proliferating epithelium of chronic wounds.
In active, ulcerative IBD, collagenases-1 and -3 and stromelysin-1 probably participate in matrix
remodeling in the granulation tissue beneath the ulcers/erosions. Matrilysin and stromelysin-2 may
be needed for the migration of intestinal epithelial cells, while macrophage metalloelastase is
involved in macrophage migration. TIMPs-1 and -3 are expressed in stromal areas corresponding to
collagenases-1 and -3 and stromelysin-1 expression, while similarly to chronic cutaneous wounds,
epithelial cells do not express TIMPs.
In conclusion, successful wound healing is accompanied by tightly scheduled expression of
metalloproteinases, their inhibitors and activators. Imbalance of the proteinases and their inhibitors
may delay wound healing and result in chronic wounds. MMPs and TIMPs are also involved in both
tissue damage and mucosal reparative processes during the course of inflammatory bowel diseases.
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